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Infection is a major medical problem that causes serious complications including 
patient death.  The mortality rate of invasive infection has reduced significantly since the 
introduction of antibiotherapy.  However, the resistance to antibiotic is becoming a 
serious medical problem that resulted in high medical cost.  The overall aim of this study 
is to evaluate a potential inorganic route (metalo-antibiotic) to treat localized infections 
that require long-term antibiotic treatment combined with medical and surgical 
intervention.  In this study osteomyelitis (bone infection) was selected as a model to 
evaluate the inorganic route to treat infection.  Osteomyelitis is a progressive infection 
that could result in amputation and patient death.  The metalo-antibiotics are faster to 
develop than antibiotics and have shown great efficacy against a wide range of bacterial 
infection.   
A unique composition of particles with ability to extend their residual efficacy on 
bacteria for an extended time compared to conventional antibiotics was synthesized and 
evaluated in this study.  The in vitro experiments demonstrated the metalo-antibiotics to 
treat cellular internal infections without damaging the home cell. The in vivo toxicity 
experiments demonstrated a tolerance of the particles for doses that are 20 times higher 
than the anticipated treatment dose.  A murine mouse model for osteomyelitis was 
developed. The efficacy of the metalo-antibiotics on the induced osteomyelitis was 
evaluated. A significant decrease in infection in the bones treated with nanoparticles was 
observed. By delivering optimal concentration of nanoparticles in mouse models there 
was no sign of pathology seen in mouse.  
Overall, this study has two main impacts: a) creation of inorganic routes to fight 
against bacterial infection particularly those requiring long-term antibiotic or surgical 
treatment b) reduction of critical technical risk through generation of pre-clinical data of 
the employment of inorganic antibacterial complexes. 
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CHAPTER I 
INTRODUCTION 
Osteomyelitis is the inflammation of bone tissue commonly caused by an 
infection.  It is a progressive infection of bone marrow and cortex [1], which results in 
not only inflammation, but also destruction, and necrosis. The populations most 
commonly affected by this infection are immunocompromised patients, surgical patients, 
elderly individuals (especially those with diabetes), and infants.  Staphylococcus aureus 
accounts for 50-75% of cases of osteomyelitis in adults and 90% of children.  Treatment 
is very extensive with prolonged delivery of antibiotics, surgery and sometimes 
imputation [1]. Pathogenesis of S. aureus-induced osteomyelitis remains poorly 
understood. Osteomyelitis infection may occur through blood stream, usually common in 
infants and children, and affect long bones, while in adults beside long bone infection it 
very often involves vertebral bones. Osteomyelitis infection can occur from nearby 
infection due to traumatic injury, surgical procedures, or use of prosthetic devices. 
Patients with diabetes who develop foot ulcers are more susceptible to osteomyelitis as 
shown in figure 1.1 weak immune system as in patients with sickle cell disease, human 
immunodeficiency virus (HIV), or patients receiving immunosuppressive medications 
such as chemotherapy or steroids were attributed to develop osteomyelitis.  
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Figure 1.1. Osteomyelitis by diabetic foot infection, image obtained from 
talkondiabeties.org 
 
The most commonly isolated gram-positive pathogen in osteomyelitis is S. aureus 
[2-4]. S. aureus is capable of colonizing in bone matrix and it is difficult to eradicate 
internalized bone infection mainly due to reduced blood supply and ischemia which 
protects the pathogen from antibiotics and immune system, which results the in long and 
expensive treatment [5-7]. Moreover, uncontrolled use of antibiotics leads to antibiotic 
resistance, more than 95% of S. aureus strains are resistant to penicillin and 40 – 50% has 
developed resistance to methicillin, making it even more difficult to treat chronic 
osteomyelitis [8, 9].  
The aim of this study is to evaluate a potential inorganic route (metalo-antibiotic) 
to fight against bacterial infections and in particular internalized bone infection.  The 
number of mortalities associated with bacterial infection is an alarming health concern. In 
2002, the US Center for Disease Control and Prevention (CDC) estimated that at least 
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90,000 deaths a year in the US could be attributed to bacterial infection, more than half 
caused by bacteria resistant to at least one commonly used antibiotic [10].  In 2009 the 
CDC reported that the number of serious methicillin-resistant S, aureus (MRSA) 
infections was close to 100,000 a year with almost 19,000 related fatalities [10].  
1.1. Internalization Of S. aureus 
Osteomyelitis induced by S. aureus is not clearly understood. S. aureus 
attachment to osteoblast cells is the first step of internalization and mechanism involves 
the surface molecules of S. aureus. It has been shown that osteoblast cells form a 
fibronectin bridge between the surface-associated fibronectin binding proteins of bacteria 
and host integrins, this bridge leads to invasion of S. aureus [11].      
Internalization requires cytoskeletal elements, including microtubules, and clathrin-
coated pits, moreover, internalization does not require live S. aureus cells [12] (live and 
dead are equally internalized); however live osteoblasts are required for invasion [13]. 
Calcium channels play a role in the rearrangement of cytoskeleton [14] which could 
contribute to bacterial invasion [14]. S aureus invasion results in phosphorylation of the 
extracellular signal-regulated protein kinases (ERK1 and 2) that in turn may cause the 
activation of transcription factors ATF-2, ElK-1 and c-Jun [15, 16].  Phospholipases-A2 
may also be activated by phosphorylated ERK-1 and ERK-2 which cause the production 
of leukotrienes [17]. This phenomenon causes the calcium channels to open on host cell 
membrane.  
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1.2. Role Of Osteoblasts In Immune Response 
Primary role of osteoblasts are to regenerate bone matrix components and regulate 
the activity of osteoclast cells, which are bone resorbing cells [18]. S. aureus is capable of 
infecting bone, utilizing adhesion molecules that help in binding to bone tissue, resulting 
in secretion of pro-inflammatory cytokines including, IL12, IL-6 and MCP-1 [19-25]. 
This in turn leads to activation of several inflammatory mediators, including 
prostaglandin E2 and RANK-L, which act to modulate the activity of bone-resorptive 
osteoclasts [26-28]. IL12 is known to protect against intracellular pathogen [29]. T 
lymphocytes and natural killer cells are stimulated by IL12 to secrete interferon (IFN), 
activating macrophages and T-lymphocytes to initiate a Th1 response [30]. The bacterial 
infection can cause the up-regulating expression of chemokine CXCL10 (IP-10). IP-10 
can recruit T lymphocytes to the site of bone infection [31]. 
Study by McCall et al [Ref] showed, S. aureus infection in osteoblasts also leads 
to the expression of NLRP3, that drives the innate immune response towards invading 
pathogens and cell damage, and maintains adaptive immune response [32, 33]. A novel 
intracellular pattern recognition receptor (NOD) expression, and Rip2 Kinase, a critical 
downstream effector molecule for NOD signaling has been observed in osteoblasts 
infected with S. aureus [34].  Bacteria invasion induced NOD expression may regulate 
pro-inflammatory pathways including Nf-κB (nuclear factor κB) and MAPKs (Mitogen-
activated protein kinase) [35].  Extensive work has been done to understand the 
mechanism of S. aureus infection and immune response to infected osteoblasts, this 
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infection continues to progress to sever condition because intracellular infection remains 
protected from humoral immune response and several class of antibiotics [36-38]. 
1.3. Apoptosis Of Osteoblast Cells By S. aureus Invasion 
Tucker et al [39] reported that bacterial infection in in-vitro causes apoptosis to 
osteoblast cells.. In apoptosis tumor necrosis factor-related apoptosis inducing ligand 
(TRAIL) is crucial step. S. aureus induced TRAIL in osteoblast cells was examined by 
Alexander et al [40], and determined that S. aureus attachment to osteoblasts is necessary 
for TRAIL induction. S. aureus induced expression of NLRP3 in osteoblasts provides a 
possible mechanism of apoptosis of host cells [32]. In general, loss of osteoblast cells 
results in bone destruction or decreased matrix deposition of bone [37]. 
1.4. Destruction Of Bone By Inflammation Or Osteoclasts 
Normal bone health and remodeling, needs the balance between osteoblast and 
osteoclast lineages [40]. This explains apoptosis alone is not responsible for bone 
destruction. However, osteoclast recruitment and other immunocytes plays significant 
role in the re-sorption and bone destruction. The stimulation of monocytes and fibroblasts 
by surface associated proteins fraction to release osteolytic cytokines including MCP-1, 
colony-stimulating factors and interleukines [25]. The macrophages and some T 
lymphocytes are recruited to areas of inflammation with the help of MCP-1 hence 
macrophages and T lymphocytes may be responsible for inflammatory damage [41, 42]. 
S. aureus infected osteoblast cells produced IL-6, may directly or indirectly modulate the 
activity of osteoclasts and may cause the differentiation of osteoclasts and osteoclast 
mediated bone mineralization [43]. Other factors like CSF is also responsible for bone 
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resorption, it has been found that high levels of granulocyte-macrophages-CSF (GM-
CSF) and G-CSF production by osteoblast infected with S. aureus may induce 
osteoclastogenesis and result in bone resorption [20].   
 In osteomyelitis patients it has been shown that 70% of all lesions mainly found in 
lower limbs, where femur and tibia accounts for 58%.  The osteomyelitis infection sites 
are shown in figure 1.2.  In chronic osteomyelitis when the bone loss is 50% or more is 
visible under X-ray, in a clinical study (figure 1.3) the chronic osteomyelitis was in tibia 
bone, however the figure also shows reconstruction of bone after treatment and 
eradication of S. aureus infection [44].    
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1.5. Treatment: Prophylaxis, Medical Or Surgical Treatment 
1. Prophylaxis 
Prophylaxis of an already established bone infection consists of intravenous 
administered antibiotics with second-generation caphalosporins being the most common 
choice [45]. During surgical operations laminar airflow is used to prevent from spreading 
airborne infections [46].    
2. Medical 
Antimicrobial drug sensitivity test is performed for isolated microorganisms. The 
antibiotic treatment is usually carried for 4 – 6 weeks, clinical and para-clinical 
parameters are monitored until complete recovery of patient [47].  
3. Surgical  
Surgical procedures are only options at certain chronic stages of osteomyelitis 
supplemented with antibiotics. The aim of surgery is to remove the necrotic and infected 
tissue surrounding infection and this is turn increase the revascularization of infected 
Figure 1.2. Sites of Osteomyelitis. (R: radius; U: ulna; T: tibia; F: fibula). 
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place [48] (see figure 1.3). In some cases surgical treatments are employed with 
supplement of beads loaded with antibiotics for slow release [49].  
 
 
Figure 1.3. Chronic osteomyelitis. (a) severe chronic osteomyelitis sequela after removal 
of a subtotal tibial shaft sequestrum. Proximal and distal metaphysis appear undamaged, 
(b) reconstruction after eradication of bacterial infection, (c) at three years post grafting. 
 
1.6. Nanoparticle Antimicrobial Therapy 
Silver nanoparticles or silver based nano-alloys have received wide attention in 
the field of nanotechnology for their attractive properties in the field of biology, 
chemistry and physics, including sensing, microelectronics, catalysis, conductivity, and 
interestingly optical properties for use in bio-diagnostics. With the exceptionally high 
extinction co-efficient of silver nanoparticles that makes its ability in Raman 
spectroscopy, led to its use in biological applications such as detection of proteins DNA 
or amino acids [50-54]. One of the most interesting features of silver nanoparticles or 
silver-alloys is its potential for antimicrobials. The global threat of microorganisms 
developing resistance against organic antibiotics enlighten research in the antimicrobial 
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properties of sliver [55]. Silver antimicrobial properties have resulted in their worldwide 
use in consumer products such as fabrics, deodorants, filters, toothpastes, washing 
machines, toys and humidifiers. Silver has been used in treatment of wounds, burns, since 
early 1900 century [56, 57]. 
Besides silver, for many years, other metals like zinc and copper have shown 
antimicrobial activity. Copper is more potent antimicrobial agent than zinc but lesser than 
silver. Copper nanoparticles has been known to have antimicrobial activity for gram 
positive and gram negative bacteria [58]. Copper nanoparticles have showed more 
interest in electronic devices. Plasmonic properties of copper have been studied recently 
and explained how copper oxide interferes with plasmon peaks [59]. Silver – copper 
alloys have recently been studied as strong antimicrobial nanoparticles comparing to 
silver alone or copper alone nanoparticles [55], it was observed silver – copper nano alloy 
has MIC of 0.5 µg/ml comparing to silver 150 µg/ml.  
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Figure 1.4. Growth of industry in silver based products 
Overall nanotechnology based consumer products including silver based products 
are growing tremendously. In recent years nanotechnology industry has shown 
tremendous growth in consumer products and linearly growing as shown in figure 14. 
Data from http://www.nanotechproject.org has shown the linear growth in last 5 years 
and has grown nearly 521% and products containing silver increased from few to over 
300 in five years. 
1.7. Aim Of The Study  
The number of mortality associated with bacterial infection is an alarming 
concern to the medical community.  It is commonly recited that the scientific community 
is only one antibiotic ahead of bacteria resistance. Inorganic nanoparticle routes to fight 
against bacterial infection has been reported for external and tropical applications, 
however internal application of these antimicrobials have not been fully explored.  Some 
of the major challenges associated with the application of metallic antimicrobial are 
associated with potential toxicity profile and method of administration to patients.  
This study aim is to evaluate a potential inorganic route (metalo-antibiotic) to 
fight against bacterial infections.  The target of this study is to evaluate the inorganic 
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bactericidal against localized infections, that require long-term antibiotic treatment 
combined with medical and surgical interventions [60]. This study focuses on 
osteomyelitis, as it is commonly believed that it is challenging to treat cellular 
internalized infections by conventional antibiotics. Osteomyelitis is progressive infection, 
which results in not only inflammation but destruction, and necrosis [61].  The organism 
that is most prevalent in cases of osteomyelitis is S. aureus [62].  
Novel classes of antimicrobial nano-alloys composed Ag-Cu-B, and Ag-Cu 
complexes [63-65] were developed.  These nano-alloys have shown noticeable 
effectiveness against both gram-positive and gram negative bacteria [66, 67], against 
fungi [68, 69], and polymicrobes [66] when compared to single element (such as silver) 
bactericidal [69]. The residual effect coupled with their non-toxicity against human tissue 
makes them a suitable candidate to be considered for the fight against bacterial infection. 
The mechanism of interaction of these metallic biocidal, which includes protein 
membrane damage, production of superoxide radicals, and release of ions that interact 
with the cellular granules and form condensed molecules [69].  
1.8. Study Scope 
In this study each chapter hereafter we will discuss as follows 
1. Synthesis of nanoparticles 
The Synthesis techniques and modifications of nanoparticles, their characterizati- 
-ion for suitable use in antimicrobial therapy.  
2. Antimicrobial activity of nanoparticles 
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This study involves the quantification of antimicrobial activity of ACL and ACB 
nanoparticles by standard method of counting bacterial colony forming units, 
spectrophotometric and bioluminescence techniques. 
3. Toxicity Assay for ACL nanoparticles 
In this study assessment of toxicity in in-vitro for ACL nanoparticles using differe- 
-nt  markers of proliferation or oxidative stress.  
4. Toxicity Assay for ACB nanoparticles 
Similar assays of toxicity like ACL were performed to assess the toxicity in in-
vitro studies, in addition several other assays were performed for cell toxicity, 
membrane damage or lipid oxidation.   
5. Toxicity in animal studies 
BALB/c animals were used in this study to assess the toxicity associated among 
vital organs. Blood profile was analyzed for hematological studies and immune 
response by B-cell proliferation. 
6. Osteomyelitis in Animal model 
Murine mouse model was established with induced osteomyelitis to study the 
antimicrobial efficiency of nanocidals which were delivered either locally or i.v. 
Further investigations of oxidative stress and histology were performed in animal 
groups used in osteomyelitis treatment.  
7. New generation Silver –Copper alloy – luminescent 
Synthesis of poly-crystalline Silver-copper glycine nanoparticles are our future 
directions to use as antimicrobial therapy. We believe they may be less toxic in 
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animals and they exhibit luminescence property which will help in tracking in-
vitro or in-vivo during treatment. 
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CHAPTER II 
SYNTHESIS OF NANOPARTICLES 
Silver nanoparticles synthesis have been reported since more than a decade, since 
then different methods have been used for synthesis and surface modification of 
nanoparticles from aqueous phase to organic phases such as micro-emulsion method by 
Sun et al. (2001) [70], reverse micelles by Taleb et al.(2000) [71], sonochemical method 
by Liu and Lin (2004) [72], silver flakes of different shapes and sizes by Wang et al. 
(2005) [73], liquid – liquid by Cai et al (2004) [74], inorganic phase by He et al. (2001) 
[75], Sun and Luo (2005) used the thermal method [76] and Lin et al. used oleic acid 
(2003) [77]. Aqueous method with sodium hydroxide and sodium acrylate has been a 
common practice for better yield of silver nanoparticles [78]. The importance of sodium 
hydroxide in synthesis of silver nanoparticles was studied by Nishimura et al [79]. Silver 
nanoparticles and silver – copper alloy have been also reported by Tanner et al [55] with 
the aid of sodium hydroxide and sodium borohydride. 
 We have synthesized silver – copper – lithium nano alloys using aqueous phase 
technique with the aid of sodium hydroxide, and silver – copper – boron nano alloys 
using boric acid along with sodium hydroxide which results in sodium borohydride.  
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 2.1. Methods And Materials For Silver – Copper - Lithium (ACL) 
Materials and chemicals: Copper (II) sulfate 99.0% Sigma Aldrich Cat# C1297, 
silver nitrate 99.999% Sigma Aldrich Cat#L9650, lithium hydroxide Sigma Cat #545856 
sodium hydroxide 97.0% Electron microscopy sciences Cat#21160, deionized water, 
heater, sand bath, double neck conical flask, Teflon rod, and homogenizer.  
Procedure.  
0.1 Molar salt of copper sulfate, silver chloride and Lithium hydroxide were 
prepared in 100ml deionized water in a ratio of 70:20:10 (Silver:Copper:Lithium).  Salt 
solution was heated at 900C temperature in a double neck flask with constant mixing by 
using Teflon rod fixed with homogenizer under the fume hood. Flask was purged with 
argon gas and continuous stream of argon used throughout the reaction, drop wise 100 ml 
of 8 M Sodium hydroxide was added from the side neck of flask and was allowed to heat 
at 900C for one hour with stirring at high speed 2000 rpm, . The suspension was allowed 
to reach room temperature and followed by centrifugation, supernatant was discarded and 
obtained pellet was washed three times by double distilled deionized water. Washed 
nanoparticles were re-suspended in 50 ml of double distilled deionized water and 
sonicated for one hour, then they were filtered through whatman filter paper and filtrate 
was freeze dried and stored in 20 ml glass vial with screw cap bottle. Prior to using the 
nanoparticles, particles were weighed from freeze dried stock and 1 mg/ml suspension 
was made and sonicated for 1 hour by using micro tip probe. In order to avoid 
agglomeration and further oxidation of copper it was immediately used post sonication.  
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2.2. Characterization Techniques  
2.2.1. Electron microscopy  
Hitachi cold FE_SEM S-4800 and Auriga Zeiss SEM were used for 
characterization of size and shape of nanoparticles. Hitachi FE-SEM S-4800 was also 
installed with Oxford EDS (Energy dispersive X-ray spectroscopy) for the elemental 
analysis; however limitation of EDS were for elements with atomic number 3 or less 
were not detected. Furthermore 100 mM of lactic acid treatment for 10 minutes was used 
to break the nanoparticles in smaller size, particles were collected by centrifugation and 
washing was repeated for 3 times to remove the lactic acid from samples. Double sided 
carbon tape SEM grade was used to load samples on SEM stub. A drop of nanoparticle 
suspension with and without sonication was placed on carbon tape attached to SEM stub 
and immediately water was evaporated under argon gas stream, after drying,  sample on 
SEM stub was placed in desiccator for overnight in order to make the sample is 
absolutely free from moisture. 
Silver-copper-lithium nanoparticles were long rectangular in shape as shown in 
Figure 2.1 (a). Nanoparticles were 100 to 200 nm long and 50 to 70 nm wide. However, 
with Lactic acid treatment, nanoparticles were spherical and average diameter of 40 nm 
as shown in figure 2.1 (c). 
  
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.2. Elemental Analysis 
EDS (Energy dispersive X-ray spectroscopy) provided the average distribution of 
elements within the nanoparticles and EDS results are summarized in Table 2.1 and EDS 
spectrum shown in figure 2.2 Silver and copper calculations came close to calculated 
ratio 70:20. EDS spectrum has shown the peaks for silver, copper and oxygen. Copper is 
Figure 2.1. ACL nanoparticles without any treatment or sonication. (A) ACL 
particles Sonicated for one hour (B). Post sonication nanoparticles treated with 
lactic acid (C). 
 
B 
C 
A 
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readily oxidized to CuO, so the presence of oxygen was fairly understood as shown in 
Table 2.1. However lithium cannot be detected because of it lower atomic number for 
Oxford EDS machine.  
 
Table 2.1.  EDS analysis of ACL nanoparticles. 
Element 
App 
Conc. 
Intensity 
Corrn 
Weight% 
Weight% 
Sigma 
Atomic% 
O K 1..77 0.7803 9.57 1.7 34.66 
Cu L 2.03 0..5293 16.21 1.89 14.77 
Ag L 15.65 0..9214 71.72 2.38 38.51 
C K 0.88 1.4931 2.5 0.89 12.06 
Totals   100.00   
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Figure 2.2. EDS spectrum of ACL nanoparticles. 
2.2.3. ICP-OES 700 
1 ml of 10mg/ml of nanoparticles was digested in 5% nitric acid with final 
concentration of 10 ppm in a volumetric flask which was covered by tin foil to protect 
from light and was kept for 2 hours at room temperature. Standard addition method was 
used to detect the concentration of silver and copper. Standard curve was generated by 
standard addition method in which samples were spiked with 1, 5 and 10 ppm from 
multi-element standard solution containing silver, copper and lithium elements in a final 
volume with 5% nitric acid. Calibration test was passed for silver, copper and lithium; the 
detection limit was 50 ppb for each element.  We found silver concentration as 7.5 ppm 
and copper 1.8 ppm which was close to our calculated ratio of 70:20 (silver:copper). 
However lithium was not detected in the nanoparticles this could be due to the fact that 
lithium may be below the detection limit. 
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2.2.4. Zeta potential 
Malvern Zetasizer – Nano Z, a laser doppler micro-electrophoresis, is used to 
measure zeta potential. An electric field is applied to a solution of molecules or a 
dispersion of particles, which then move with a velocity related to their zeta 
potential. This velocity is measured using a laser interferometric technique called 
M3-PALS (Phase analysis Light Scattering). This enables the calculation of 
electrophoretic mobility and from this the zeta potential for the accurate 
measurement of wide variety of sample types and dispersion media including high 
salt concentration and zeta potential distribution.  The zeta potential for the particles 
is shown in figure 2.3. The zeta-potential of silver-copper-lithium nanoparticles was 
found to be -29 mV, which explains the moderate colloidal suspension; negative 
zeta-potential also depicted the oxidation of copper on surface of nanoparticles. 
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Figure 2.3. Zeta potential of silver copper lithium nanoparticles. 
2.3. Methods And Materials For Silver-Copper-Boron Nanoparticles (ACB) 
Copper (II) sulfate 99.0% sigma Cat#C1297, silver nitrate 99.0% Sigma 
Cat#s6506, sodium hydroxide 97.0% Electron microscopy sciences Cat#21160, Boric 
acid 99.5% Sigma Cat# B6768, deionized water, heater, sand bath, double neck conical 
flask, Teflon rod, and homogenizer were available in lab. 
Silver-copper-boron (ACB) was synthesized by preparing 0.1 M salt of silver 
nitrate, copper sulfate and boric acid in a ratio of 70:20:10 respectively. Solution was 
heated up to 90o C in a triple neck flask under vigorous stirring by Teflon double blade 
with the aid of homogenizer with continuous flow of argon gas. 8 M NaOH was added 
drop wise until the formation of black precipitate and heated for 20 minutes, precipitate 
turned to greyish black. The precipitate formed was washed repeatedly more than three 
times in deionized water by centrifugation at 4000 rpm for 10 minutes. Final pellet was 
sonicated for one hour on ice bath to reduce the temperature rise during sonication.  After 
sonication sample was filtered through Whatman filter paper and nanoparticles were 
22 
 
obtained from filtrate by centrifugation at 4000 rpm. Pellet obtained was freeze dried and 
were stored in a glass vial with airtight screw cap. Prior to using the nanoparticles, 
particles were weighed from freeze dried stock and suspended in deionized water 
followed by sonication and were used immediately. Every time nanoparticles are weighed 
fresh from freeze dried stock for each experiment. Old stock in suspension was discarded 
because of copper oxide growth leads to aggregation of nanoparticles.  
2.3.1. Characterization techniques  
SEM Hitachi S-4800 with EDS Oxford, Auriga Zeiss SEM, Zeta sizer ZS – 
Malvern, ICP-OES – 700 Agilent, was used for characterization of size and shape as 
mentioned earlier. In addition XRD – diffractometer (Agilent/Oxford Gemini) was used 
to confirm the crystal structure of silver –copper –boron nanoparticles.  
2.3.2. XRD – Diffractometery 
The XRD technique (Molybdenum source: Voltage 50 kV and with 30 mA 
current and λMo= 0.709 °A) was used to study the phase formation and morphology in the 
Ag-Cu-B system.  The major diffraction peaks of silver are clearly seen and indexed in 
the figure 2.4 and Table 2.2. A considerable amount of the CuO and the Cu2O phases are 
also formed in the microstructure of the alloy. From the calculations of the peak 
intensities and the d-values of the atomic spacing, a relatively high degree of crystallinity 
is observed. However, no traces of boron and its phases have been observed in this 
pattern.  It is well known that the behavior of boron depends upon the crystallinity of the 
sample, temperature, particle size, and purity. At higher temperatures, boron does burn to 
form boron (III) oxide, B2O3. However, due to the low reactivity of boron with silver at 
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relatively low temperature, the XRD pattern was not able to reveal the boron peaks or any 
related phases. It is also worth mentioning that the addition of small amount of boron 
nanoparticles below the detection limit of the diffractometer may explain the absence of 
the boron peaks. Moreover, for alloys with small copper concentrations, it is difficult to 
incorporate boron in the alloy due to low solubility of boron in a silver-rich phase. 
Therefore, in this study our aim is to look for the optimum dose of the Ag-Cu base alloy, 
which will be ideal for the incorporation of maximum amount of boron. It is suggested 
that the boron content in the Ag-Cu system increases within the copper rich (dark) 
phases. 
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Figure 2.4. Powder graph of Silver-Copper-Boron. 
Table 2.2. XRD diffraction peaks of Ag, CuO and Cu2O. 
 2theta [degree] 
Cu2O 8.69 21.81 29.68 34.92 
Cu0 15.41 26.86 44.42  
Ag 17.37 28.43 33.3  
 
2.3.3. Scanning Electron Microscopy 
SEM characterization was followed as mentioned earlier. SEM Images of Ag-Cu-
B nanoparticles showed nanoparticles are rectangular in shape with average size ranging 
between 80 to 140 nm. However, with lactic acid and sonication treatment was effective 
to reduce the size between 15 to 20 nm. Size measurements were performed by Quartz-8 
imaging software as shown in Figure 2.5.  
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2.3.4. Energy dispersive X-ray spectroscopy (EDS) 
Elemental identification and semi-quantitative analysis was provided by EDS 
Oxford spectroscopy by using INCA software, sample was analyzed by Point and ID 
protocol, which is bulletin option in INCA software for acquiring X-ray spectrum from 
point of interest. As shown in Figure 2.6, only two nanoparticles were selected to get the 
X –ray spectrum in order to minimize the interference from surrounding materials and 
shown the distribution of elements in each particle. The results are summarized in table 
Figure 2.5. SEM images and Histogram of nanoparticles. Upper and lower 
histograms shows without or with Lactic Acid treatment respectively. 
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2.3 which are generated directly by INCA software for each spectrum and are exported 
into word file.  
 
Table 2.3. EDS analysis of ACB nanoparticles. 
Element App Intensity Weight% Weight% Atomic%  
    Conc. Corrn.  Sigma    
O K 50.17 0.3280 12.41 1.21 45.64  
Cu K 208.96 0.9770 17.36 0.39 16.07  
Ag L 807.91 0.9337 70.23 1.02 38.29  
Totals   100.00    
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Silver, copper and oxygen ratio was 70.23, 17.36 and 12.41 respectively as shown 
in figure 2.6; Copper is oxidized rapidly so the oxygen was expected to be associated on 
the surface of nanoparticles. Boron was difficult to identify by EDS because of lower 
atomic number. 
2.3.5. ICP –OES 700 
The procedure for ICP-OES by standard addition was same as described earlier 
for Silver–copper-lithium nanoparticles. All three elements were quantified by ICP-ES 
spectroscopy as shown in Figure 2.7; data provided the elemental ratio within 
nanoparticles such as 6.9 ppm, 2.06 ppm and 1.4 ppm of silver copper and boron 
respectively from a 10 ppm nanoparticles suspension. It is obvious from the data (figure 
2.7) that 1 µg of ACB nanoparticles will have 690 ng, 200.6 ng and 140 ng of silver 
copper and boron respectively.  
Figure 2.6. EDS spectrum silver –copper –boron nanoparticles. Electron 
image acquired by point selection. 
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2.3.6. Zeta potential 
Zeta potential for silver –copper –boron was studied to measure the quality of 
dispersion of nanoparticles in aqueous solution and the surface charge on nanoparticles. 
The zeta-potential measured for silver –copper –boron nanoparticles was -30mV as 
shown in figure 2.8  
The effect of glacial acetic acid, on ACB nanoparticles a shift in zeta-potential 
from -30 mV to +3 mV was observed (figure 2.9). The glacial acetic acid reacts of copper 
oxide and not with metal copper [59]. Copper oxide reaction with glacial acetic acid as 
follows:  
  
Figure 2.7. ICP-OES of silver –copper –boron nanoparticles. 
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 (1) CuO + 2CH3COOH    Cu(CH3COO)2 + H2O 
 (2) Cu2O + 4CH3COOH    2Cu(CH3COO)2 + H2O + H2  
Copper has low reduction potential of (0.34 V) Cu0/Cu2+ comparing to silver (0.8 
V) [55], hence it is problematic that silver –copper nanoparticles can have copper oxide 
growth on their surfaces. Freeze drying in inert atmosphere reduces the oxidation of 
copper. ACB particles were functionalized with mercaptopropionic acid which has thiol 
group with high affinity towards metals. Mercaptopropinic acid was added to 1 mg/ml of 
ACB nanoparticles at a final concentration of 100 mM and incubated for 30 minutes with 
3 seconds sonication after every 10 minutes. Latter particles were centrifuged at 13000 
rpm for 10 minutes and pellet was resuspended in deionized water, this procedure was 
repeated 5 times to remove the unbound Mercaptopropionic acid. The zeta-potential was 
-30 mV (Figure 2.10) that may be due to carboxylic group available on the surface of 
nanoparticles.  Further tuning was done by conjugating with polyethylineamine (PEI) by 
using EDC (1-Ethyl-3-carbodiimide hydrochloride)  coupling (see figure 2.11) [80]. Zeta-
potential after conjugating with PEI, flip from -30 mV to + 60 mV (Figure 2.10). Positive 
zeta-potential is believed to be due to amine terminal groups.  
This study suggests that these nanoparticles can be functionalized by organic 
molecules and polymers to make them aqueous soluble nanoparticles and the risk of 
toxicity can be reduced.  
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Figure 2.9. Zeta-potential after glacial acetic acid treatment. 
Figure 2.8. Zeta potential of ACB nanoparticles after sonication. 
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Figure 2.10. Zeta-potential of functionalized nanoparticles. Left red peak is after 
ACB nanoparticles are functionalized with 3-Mercaptopropionic acid, green peak 
in the middle after treatment with glacial acetic acid, blue peak on Right after 
conjugation of PEI with 3-Mercaptopropionic acid. 
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Figure 2.11. Schematic representation of nanoparticle tuning. 
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CHAPTER III 
ANTIMICROBIAL ACTIVITY OF NANOPARTICLES 
The antimicrobial nature of the silver and copper are well documented.  In this 
chapter our aim was to evaluate the antimicrobial efficacy of the silver-copper-lithium 
and silver-copper-boron against S. aureus. 
3.1. Antimicrobial Activity Of Silver-Copper-Lithium 
3.1.1. Materials and methods 
The S. aureus strain used in this study was obtained from ATCC (Cat# 700260). It 
was streaked on T. soy agar plates. Stock was stored in glycerol at -80°C. Bacterial 
colonies, grown on T. soy agar plates, were inoculated into a 5 ml of T-soy broth and 
cultured stationary overnight at 37°C with aeration. The overnight grown bacterial 
suspension was then sub-cultured at 1:5 ratio and grown to mid-log phase for another 2 
hours with shaking at 200 rpm and was stopped when O.D. reached to 0.5 at 600 nm 
which were equivalent to 5×107 CFU/ml.  Cells were harvested by centrifugation for 20 
minutes at 4300g and pellet was washed with PBS. Serial dilutions were prepared in 
sterile T-soy broth and used at initial concentration of 5× 105 CFUs per ml for each 
experimental sample. 
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3.1.2. Antimicrobial effect of ACL 
The antimicrobial assay was performed in duplicates with different groups by 
incubating 5× 105 CFUs/ml of S. aureus bacterial suspension. Each group with different  
concentrations of ACL nanoparticlexs at 10, 5, 1, 0.5 and 0.01 µg/ml and were grown at 
37°C for 24 hours in an orbital shaker. Post 24 hours culturing, serial dilutions were then 
made in sterile PBS buffer for each group and 100 µl aliquots were plated on T-soy agar 
plates. Bacterial colony forming units (CFUs) were enumerated after overnight  incubat-
ion  of S. aureus with different concentrations of nanoparticles resulted in a substantial 
reduction in the number of viable S. aureus organisms (Figure 3.1). The degree of inhib-
ition  was dependent on the concentration of nanoparticles used, such as CFUs reduction 
by 4.8 logs, 3.6 logs, 3 logs for 5 µg/ml, 1 µg/ml and 0.5 µg/ml respectively. While as 
0.01 µg/ml concentration of nanoparticles did not show inhibition of S. aureus growth. 
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Figure 3.1. Antimicrobial activity of ACL Nanoparticles. S. aureus bacteria were 
incubated with different concentration of ACL nanoparticles for 24 hours, each bar 
represents the reduction in CFUs. 
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3.1.3. Effectiveness of ACL nanoparticles on S. aureus-infected osteoblasts 
Human osteoblast cell culture and invasion assay 
The hFOB 1.19 human osteoblast cell line was obtained from ATCC (Cat# CRL-
11372). Cells were cultured as per ATCC recommendations in 10% FBS phenol free 
DMEM: F12 and G418 – 300 µg/ml. Osteoblast cells were cultured in a 6-well plate to 
90% confluency. Cells were washed with antibiotic free media six times, and then 
infected with S. aureus at a ratio of 250:1 (MOI=250:1) for two hours. Cells were then 
washed three times with antibiotic free media and incubated in medium containing 200 
µg/ml of gentamicin for 2 hours to eradicate non-internalized bacteria. After another 
cycle of three washes, nanoparticles were added at a final concentration of 1, 5, or 10 
µg/ml to the osteoblast cell cultures in an antibiotic free media and incubated for further 
24 hours. Control was grown under similar conditions except nanoparticles were not 
added to culture. Cells were then washed again three times and harvested after 
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trypsinization in 1 ml of 0.25 % of trypsin (Sigma Aldrich Cat # T 4049). Cell lysates 
were prepared in 0.5 ml of lyses buffer (PBS+0.1% Triton X-100) and serially diluted in 
1 ml of PBS buffer. 100 µl from each dilution was plated on T-soy agar plate and 
incubated overnight for enumeration of intracellular bacterial CFUs. Similar assays were 
repeated using a fixed concentration of 1 µg/ml of nanoparticles and varying the 
incubation time with the infected osteoblasts from 17 to 80 hours.  
Antimicrobial activity 
To assess the potential antimicrobial activity of ACL nanoparticles on infected 
osteoblasts, experiments were carried out on S. aureus-infected osteoblasts using three 
different concentrations of nanoparticles (1, 5, and 10 µg/ml). The experimental set up 
was designed to specifically evaluate the effectiveness of the nanoparticles against 
bacterial organisms, which have invaded the osteoblasts, thereby mimicking the 
conditions of human osteomyelitis. As can be seen from figure 3.2, the effect of 
nanoparticles on osteoblast-internalized bacteria was very significant. At a nanoparticle 
concentration of 1 µg/ml, there was 43% reduction in bacterial CFU’s; the degree of 
inhibition was increased to 97% at nanoparticle concentrations of 5 and 10 µg/ml as 
shown in figure 3.2. Similar assays were carried out by fixing the concentration of 
nanoparticles to 1 µg/ml and varying the incubation period of infected osteoblasts with 
the nanoparticles (17, 48, 60 and 80 hr). The results of these studies are depicted in figure 
3.3, which shows effectiveness of antimicrobial activity increased with prolonged 
incubation time. Using the sub-optimal concentration of 1 µg/ml, while degree of 
inhibition was only 32% after 17 hour of incubation, whereas inhibitory effect to > 95% 
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by 45 hours (Figure 3.2). These experiments bring out that antimicrobial efficacy may be 
dependent on both incubation time and concentration of nanoparticles. This data 
demonstrated that the addition of nanoparticles at concentrations as low as 0.5 µg/ml 
resulted in a more than 50% inhibition S. aureus bacterial growth within 24 hrs and while 
as 1 µg/ml also showed more than 99% MBC, Based on our bactericidal findings, here 
similar dose and higher concentrations up to 15 µg/ml to find the cellular toxicity.  
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 Figure 3.2. Effect of ACL on internalized bacteria. 
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3.2. Antimicrobial Efficacy Of Silver-Copper-Boron Nanoparticles 
Silver –copper –boron (ACB) nanoparticles, synthesis and characterization 
described in chapter 2. Antimicrobial activity evaluation of ACB were performed similar 
to ACL nanoparticles using the same strain of S. aureus and for invasion assay same cell 
line of osteoblast cells were used, however the antimicrobial activity was performed in 
Osteoblast cell culture media (DMEM:F12 with L-glutamine and 10%FCS) instead of 
Tryptic Soy Broth.  In addition to S. aureus, another strain XEN 36 which was obtained 
from Caliper life science, Xen36 was derived from the parental strain S. aureus ATCC 
49525 (Wright), a clinical isolate from bacteremia patient. S. aureus. Xen-36 possesses a 
stable copy of the modified Photorhabdus luminescence lux ABCDE operon at a single 
integration site on a native plasmid. Xen-36 should be stored at -80°C. 
3.2.1. Bacterial strain and growth 
The S. aureus strain used in this study was obtained from ATCC (Cat# 700260) 
and kept as frozen glycerol stocks at -80°c. Bacterial colonies, grown on trypticase soy 
 Figure 3.3. Time dependent Effect of ACL on internalized bacteria. 
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agar plates, were inoculated into a 5 ml T-soy broth and cultured stationary overnight at 
37°C with aeration. The bacterial suspension was then sub-cultured at 1:5 ratios and 
grown to mid-log phase for another 2 hours with shaking. Cells were harvested by 
centrifugation for 20 minutes at 4300g and pellet was washed with PBS. Cell density was 
measured spectrophotometrically. Serial dilutions were prepared in sterile PBS buffer and 
used at 1× 105 CFUs per experimental sample. 
3.2.2. Antibacterial effect of ACB nanoparticles against S. aureus 
The assay was performed in a 24 well corning cell culture plate in a final volume 
of 1 ml by incubating S. aureus with cell density of 1× 105 CFUs / ml in a  DMEM:F12 
media with L-Glutamine (Cat. No 21041025) and 10% Fetal calf serum (FCS) with or 
without different concentrations of nanoparticles 1, 5, 10, 20 and 30 µg/ml the suspension 
was incubated in a dry incubator overnight and absorbance was measured at 600 nm 
using BioTek spectrophotometer. Furthermore similar assay were done in 96 well plate in 
200 µl volume with or without nanoparticle concentrations 1, 2, 3, 4 and 5 µg/ml. After 
incubation time bacterial cells were harvested by centrifugation and resuspended in 1ml 
of warm PBS buffer pH 7.4 and were serially diluted and 100 µl was poured in TSB-agar 
culture plate and incubated at 37 degree C. overnight and following day CFU’s were 
counted. Incubation of S. aureus with nanoparticles at different concentrations resulted in 
substantial reduction in number of viable S. aureus microorganism Figure 3.4. The 
degree of reduction was dependent on the concentration of nanoparticles and incubation 
time and was observed as O.D. value at 600 nm, where 1µg/ml concentration exhibited 
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28 % inhibition by while 5, 10, 20, 30 µg/ml concentration inhibited from a range of 90 
to 99%. 
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Figure 3.4. Antimicrobial activity of ACB nanoparticles. 
 
3.2.3. Antimicrobial activity in XEN-36 and native S. aureus strain 
Similar antimicrobial testing of ACB nanoparticles ranging from 1, 2, 3, 4, and 5 
µg/ml against S. aureus in 1 ml cell culture media was performed as mentioned earlier. 
Moreover XEN-36 bacterial strain, which is bioluminescent, was also utilized.  In 
addition to O.D. measurements, Biotek Luminometer was utilized to measure Bio-
luminescence for treated and non-treated XEN-36 bacterial strain. Bioluminescence 
methods have used to for analysis efficacy of antimicrobial compounds [81]. 
Vancomycin was also used as control to evaluate the antimicrobial activity of the 
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particles against a known antibiotic. Vancomycin remains the standard of care for 
treating serious methicillin-resistant S. aureus (MRSA) infections. However, vancomycin 
resistant S. aureus (VRSA) was reported first from a renal dialysis patient in 2002 in 
Michigan [82]. XEN-36 and parental strain S. aureus both were susceptible to 
vancomycin. The MIC of vancomycin against S.aureus was determined as 0.5 µg/ml 
[80]. 
Antimicrobial activity of ACB nanoparticles using 1, 2, 3, 4 and 5 µg/ml 
concentration showed that XEN-36 strain and native S. aureus have similar behavior. 
Antimicrobial activity in a narrow range from 1 µg/ml to 5 µg/ml concentration was 
observed, where 1 µg/ml has 0.5 log difference comparing to control which corresponds 
to 63.8 % reduction while 2 µg/ml has 5 log difference and 3, 4 and 5 µg/ml has more 
than 5 log difference compared to control which corresponds inhibition by greater than 
99% as shown in figure 3.5. 
Bioluminescence based assay results showed similar pattern of inhibition for 
vancomycin and ACB nanoparticles. Bioluminescence method as shown in figure 3.6 
was used to evaluate the degree of inhibition.    
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Figure 3.5. Antimicrobial activity in XEN-36 strain and native s. aureus. Upper graph 
represents the reduction in number of Log CFU XEN 36, and lower graph represents the 
reduction in number of Log of CFU S. aureus 
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Figure 3.6. Bioluminescence measurements of XEN-36. Upper graph showed the 
antimicrobial activity by ACB nanoparticles whereas bottom graph represents the 
antimicrobial activity by antibiotic vancomycin. 
 
3.2.4. Antimicrobial activity on osteoblast cells invaded by S. aureus 
Osteoblast cell invasion assay was performed as discussed in section 3.1.4. 
Osteoblast cells infected with S. aureus with MOI of 250:1.  To assess the antimicrobial 
activity of internalized bacteria, here in this study the dose was used as 1 µg/ml and 5 
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µg/ml concentration for 24 hours and 48 hours incubation time. In 24 hour incubation 
time with 1 µg/ml viable count of internalized bacteria was 1.5 logs less comparing to 
control as shown in Figure 3.7, while in 48 hours incubation time was seen 4.5 logs 
down. Similarly, 24 hour incubation time with 5 µg/ml of concentration showed 
inhibition of infection by 2.5 Logs and while in 48 hours incubation S. aureus infection 
was inhibited by 7.5 logs. 
In this study the developed ACB nanoparticles are capable of eliminating the 
intracellular infection in osteoblast cells similar to ACL nanoparticles; however the 
antimicrobial activity of ACL was significantly higher than ACB nanoparticles. The 
importance of ACB nanoparticles over ACL is that, that cellular toxicity will be less 
comparing to ACL. As will be shown in chapter 4, it was found that ACL nanoparticles 
exhibited toxicity at 10 µg/ml so the target is to produce equally effective antimicrobial 
nanoparticles with less toxicity in eukaryotes. In this study it is shown that 1 µg/ml was 
effective antimicrobial activity in 48 hours it has shown reduction by 4.5 logs which is 
close to 99.9% inhibition of infection.  The cellular toxicity assays associated with ACB 
nanoparticles will be explored. 
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Figure 3.7. ACB – Invasion Assay. Antimicrobial activity of internalized bacteria in 
osteoblast cells. 
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CHAPTER IV 
TOXICITY ASSAY FOR ACL NANOPARTICLES 
Four different assays were used to determine the potential toxicity of 
nanoparticles on osteoblasts. These assays measure the degree of cell 
survival/proliferation (MTT assay), or degree of cellular oxidative stress (L-Glutathione 
depletion, catalase activity and protein carbonyl content).  
4.1. MTT Proliferation/Survival Assay 
This is simple method for determining cell viability or proliferation. MTT assay 
developed by Mossman is still among one of the most versatile and popular assays. The 
MTT assay involves the conversion of the water soluble MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) to an insoluble formazan.2-4. The formazan is then 
solubilized, and the concentration determined by optical density at 570 nm.  
Kit was purchased from Invitrogen (Cat# M-6494), standard protocol was followed as 
directed by company in a 96 well plate with 10,000 osteoblast cells / well and 
nanoparticles with concentrations 1, 5, 10 and 20 µg/ml were added to different wells and 
incubated for 24 hours, after incubation nanoparticles were washed and MTT assay was 
performed as directed by kit. By pipetting insoluble pellet was dispersed and absorbance 
was measured at 570/630 nm. 
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The co-culture of osteoblasts with nanoparticles for 24 hours at concentrations of 
1 or 5 µg/ml had no effect on viability as shown in Figure 4.1. Cell viability was reduced 
by 25% and 70% when nanoparticle concentration was increased to 10 or 20 µg/ml, 
respectively; however, 10 µg/ml was statistically non-significant.    
It is concluded from the MTT assay, that ACL nanoparticles may be toxic from 10 µg/ml 
concentration.  Further oxidative stress markers will be used in this study to see if less 
than 10 µg/ml can be toxic to the cell.  
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Figure 4.1. MTT assay. Osteoblast cells treated with ACL nanoparticles.   
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4.2. Oxidative Stress Assays 
 Osteoblast cells were grown in T-25 culture flasks. When cells were 90% 
confluent different concentration of nanoparticles as 1, 5, 10 and 15 µg/ml were added 
and incubated for 24 hours. After incubation cells were washed by PBS buffer pH 7.4 and 
lysed in a 1 ml of lysis buffer pH-8.8 (50mM of Tris and 1mM EDTA) by cell disruptor 
in cold conditions. Cells were centrifuged at 10,000g for 10 minutes in a cold centrifuge 
and supernatant was collected for glutathione assay, catalase activity and carbonyl 
content. Total protein obtained from supernatant was measured by BCA assay Cat: No. 
23227 
4.2.1. Glutathione assay  
Glutathione is a tripeptide comprised of cysteine, glycine and glutamate. It is an 
antioxidant, preventing damage to cellular components caused by reactive oxygen species 
such as free radicals and peroxides. GSH reduces disulfide bonds formed within 
cytoplasmic proteins to cysteines by serving as an electron donor. In this process GSH is 
oxidized to glutathione disulfide (GSSG). Reduced glutathione (GSH) was measured by 
Coleman et al [83]. 2.5 mM of GSH (L-Glutathione) cat# G6013 from sigma, was made 
in Tris EDTA pH 8.8 buffer, and was serially diluted in Tris-EDTA buffer in a 96 well 
plate.  Each well was added with 100 µl of 2.5 mM of 5,5′-Dithiobis (2-nitroobenzoic 
acid) DTNB Cat# D8130) from sigma, which was prepared in Tris-EDTA buffer. Plate 
was incubated for 10 minutes and absorbance was measured at 405 nm. A standard curve 
was generated from GSH in nanomoles verses Absorbance measured. 100 µl of 
supernatant of different samples were added to different wells of 96 well plate and 
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followed by addition of 100 µl of 2.5 mM DTNB reagent and incubated for 10 minutes, 
absorbance was measured at 405 nm and concentration of reduced glutathione was 
calculated from standard curve. Concentration of reduced glutathione for each sample 
was normalized with total protein of each sample and GSH concentration was expressed  
in nmoles/mg of total protein. 
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4.2.2. Catalase assay and protein carbonyl assay 
Catalase activity and protein carbonyl content of samples from supernatant of cell 
lysate was measured by the help of catalase assay kit and protein carbonyl kit 
respectively and both the kits were used as directed by the manufacturer and were 
Figure 4.2. GSH assay. ACL nanoparticles were incubated with osteoblast cells for 
24 hour, post incubation GSH concentration was measured from soluble proteins. 
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purchased from Cayman, Catalase Assay kit Cat. No.707002 and Protein carbonyl assay 
kit Cat. No. 10005020.  
4.3. Results And Discussion  
The antioxidant activity was measured by determining the levels of reduced 
glutathione in osteoblast cell cultures after treatment with nanoparticles at different 
concentrations for 60 hours. As shown in Figure 4.2, no significant decrease in reduced 
GSH levels was observed up to a concentration of 15 µg/ml of nanoparticles. 
The protein carbonyl content was determined in the culture supernatants of 
osteoblasts after co-culture with nanoparticles. The results, shown in Figure 4.3, indicate 
that essentially no change in protein carbonyl content was observed when cells were 
treated with up to 5 µg/ml of nanoparticles. When nanoparticles concentration was 
increased to 10 µg/ml, a slight but insignificant increase was observed. However, at 15 
µg/ml concentration, there was >2.5-fold increase in protein carbonyl content which was 
statistically significant, suggesting that there is an increase in protein oxidation at higher 
concentrations of nanoparticles. In a fourth assay,  the level of catalase activity was 
measured, an antioxidant enzyme responsible for the detoxification of hydrogen peroxide, 
a reactive oxygen species (ROS) and a toxic product of both normal aerobic metabolism 
and a reactive oxygen intermediate produced in response to microbial pathogens by 
inflammatory cells. The results of this assay demonstrate that there was a gradual 
decrease in catalase activity with increasing concentration of nanoparticles Figure 4.3. 
However, significant reduction in catalase activity was only seen at nanoparticles 
concentrations 10 µg/ml and above. Taken together, the cellular toxicity data demonstrate 
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that nanoparticles induce significant toxicity in osteoblasts at concentrations of ≥ 10 
µg/ml. Since our study  have shown that nanoparticles are effective against intracellular 
S. aureus organisms at 1 µg/ml concentrations, our findings demonstrate that there may 
be no toxic side effects of nanoparticles on osteoblasts at 1 µg/ml concentration.    
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Figure 4.3. Protein carbonyl and Catalase measurement Assay. Upper figure protein 
carbonyl assay and lower figure catalase assay for ACL nanoparticles. 
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CHAPTER V 
CELLULAR TOXICITY FOR ACB NANOPARTICLES 
Toxicity of ACB nanoparticles was assessed similar to ACL nanoparticles, 
however in addition LDH (lactate dehydrogenase assay); SOD (super oxide dismutase 
assay) and membrane lipid oxidation assay using C11-BODIPY 581/591 experiments were 
performed. Cell proliferation assay WST-1 assay was used instead of MTT assay which 
forms soluble salt in aqueous so easier to perform; otherwise both have almost similar 
antimicrobial efficiency and sensitivity.  
5.1. Toxicity Assays Of ACB Particles 
5.1.1. LDH assay 
LDH assay can be performed by assessing LDH (lactate dehydrogenase) release 
in to the media as a marker of dead cells or membrane damage. CytoTox-ONE assay kit 
was purchased from Promega Cat. No. G7890. It is a fluorescent measure of the release 
of lactate dehydrogenase (LDH) from cells with damaged membrane. In this assay 
conversion of resazurin into resorufin which is a fluorescent with excitation wavelength 
560 nm and emission wavelength at 590 nm. Experiment was performed in a 96 well 
plate with osteoblast cells 10,000 per well. Nanoparticles were added to each well with 
different concentration from 1 µg/ml to 20 µg/ml concentration and were incubated for 
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24 hours. LDH assay was performed as directed by manufacturer; fluorescence was 
measure by using Biotek plate reader.  
 
5.1.2. WST1 Proliferation / survival assay  
WST1 Kit was purchased from Clontech (Cat. No. 630118) and was used as 
directed by company in a 96 well plate with average of 10,000 cells/well in a DMEM: 
F12 with L-glutamine and 10% Fetal Calf Serum (complete media) and nanoparticles 
with concentration 1, 5, 10, 15, 20, and 30 µg/ml were added and incubated for 24 hours, 
after incubation each well was washed with PBS buffer to remove nanoparticles and fresh 
media was added and WST1 assay was performed as directed by manufacturer. 
Absorbance was measured at 450 nm. 
5.1.3.  Oxidative stress measurement assays 
Osteoblast cells were grown in a T-25 flask. Different concentrations (1, 5, 10, 15, 
20 or 30 µg/ml) of ACB nanoparticles were added and incubated for 24 hours. After 
incubation cells were washed with PBS buffer pH 7.4 and lysed in a lysis buffer pH 8.8 
(50 mM of Tris and 1 mM of EDTA) with protease inhibitor (Sigma Cat. No. P8340) by 
cell disruptor in cold conditions. Cell lysate was collected in eppendorf tube and 
centrifuged at 10,000g for 10 minutes in cold centrifuge and supernatant was collected 
for glutathione assay, catalase activity and carbonyl content. Total protein content in the 
supernatant was measured by BCA assay and kit which was purchased from Thermo 
Scientific Cat. No. 23227 and was used as directed by manufacturer, reagents A and B 
were mixed in 50:1 ratio and 180 µl of mixture of A and B was added to 20 µl of sample 
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or dilutions of standard curve in a 96 well flat bottom plate. Plate was covered and 
incubated for 30 minutes. Absorbance was measured at 562 nm by Biotek Plate Reader.  
5.1.4. Glutathione (GSH) assay 
Biochemical assay by Coleman et al.[83] was performed to detect the reduced 
glutathione from the supernatant of cell extract. 2.5 mM of reduced GSH was dissolved 
in 10 ml of Tris EDTA buffer and 2.5 mM of DTNB were dissolved in 10 ml of Tris-
EDTA buffer pH 8.8, 100 µl of GSH with different molar concentrations were pipetted 
out in a 96-well plate and then 100 µl of DTNB was added to each 96-well. Absorbance 
was measured at 405 nm and standard curve was plotted. 100 µl of supernatant from 
treated or non-treated cells were added to 96-well plate and 100 µl of DTNB reagent was 
added. Absorbance was measured at 405 nm and concentration of reduced glutathione 
was calculated from standard curve.  
5.1.5. Protein carbonyl and catalase assay  
Protein carbonyl content nmoles/ml was measured from supernatant of treated 
cells with the help of protein Carbonyl kit which was purchased from Cayman, Cat. No. 
10005020. Catalytic activity in nmoles/min/ml was measured from supernatant of treated 
or non -treated cells with the help of Catalase kit purchased from Cayman Cat. No. 
707002. 
5.1.6. Super oxide dismutase (SOD) assay 
Cayman’s superoxide dismutase assay kit utilizes a tetrazolium salt for detection 
superoxide radicals generated by xanthine oxidase and hypoxanthine. One unit of SOD is 
defined as the amount of enzyme needed to exhibit 50% dismutation of the superoxide 
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radical. The SOD assay measures all three types of SOD (Cu/Zn, Mn, and FeSOD). The 
assay was performed as described by manufacturer (Cayman Cat # 706002).   Osteoblast 
cells were grown in T-25 flask cell and at 70% confluency, fresh media was fed to the 
cells and treated with different concentration of nanoparticles ranging from 1 µg/ml to 20 
µg/ml and were incubated for 15 hour hours (overnight incubation) or 48 hours (two 
days). Post incubation cells were harvested by gently scrapping using rubber policeman 
and cells were homogenized in a recommended buffer by manufacturer as mentioned in 
the kit. Standard curve was generated under the instructions of manufacturer and cellular 
SOD was calculated.   
5.1.7. Ration- fluorescence assay of C11-BODIPY 581/591 
Lipid oxidation in cellular membranes has been monitored by undecylamine 
fluorescein and Hexadecanoyl BODYIP-FL, which monitors only non-oxidized form of 
these fluorophores, however BODYIP 581/591 is very suitable for ratio-fluorescence of 
oxidation process in membranes of living cells [84]. In another study, it was reported that 
C11-BODIPY is susceptible to oxidation and thereby losing its bright red fluorescence 
and shifting towards shorter wavelength of excitation and emission 500/510, both spectra 
are well separated and are used to quantify the fraction of oxidized and non-oxidized 
C11-BODIPY 581/591 simultaneously at any time point.  These fluorophores are called as 
surrogate markers of lipid peroxidation [84, 85]. 
Here fluorophores were used to study the oxidation of membrane lipids in 
osteoblast cells grown in costar flat bottom 96 well plate. Initially cells were treated with 
different concentration of nanoparticles of 1, 5, 10, 15, and 20 µg/ml and were incubated 
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for 24 hours, post incubation cells were washed with PBS buffer pH7.4 Ca++ and Mg++ 
free and fed with 100 µl of warm fresh PBS buffer and 5 µM of C11-BODIPY 581/591 was 
added to each well. Positive control well 5 mM or 10 mM of hydrogen peroxide was 
used and incubated for 30 minutes at room temperature.  Fluorescence was measured at 
both wavelengths at the following excitation and emission 575/595 and 505/515 for red 
and green respectively using Biotek Fluorometer. Data was normalized to percent by 
taking 10 mM of hydrogen peroxide as positive control 100 % emission for green 
fluorescence while as negative control was taken as 100% emission for red fluorescence.    
5.2. Confocal Microscopy  
Osteoblast cells were grown on 18 mm sterile cover slips in a 6 well plate and 
were cultured up to 60 % confluency. Internalization of bacteria was performed as 
discussed earlier followed with treatment with nanoparticles with 3 µg/ml, and incubated 
24 hours.  Cells were washed again with pre-warmed PBS buffer three times and were 
semi fixed for stability to keep internalized bacteria alive in a 0.5 % formalin for 10 
minutes. Post fixation, cells were again washed thrice with PBS buffer and 0.05 % of 
saponin (Cat. No. 47036, sigma) in PBS was added and incubated for 20 minutes, which 
permeabilized osteoblast cell membrane for propidium iodide dye. Confocal microscopy 
was used to detect live and dead bacteria; the stain used was from Invitrogen Cat. No. L-
7012 with two types of dyes SYTO 9 dye component A and propidium iodide component 
B. Both the components were mixed in 1:1 ratio final volume of 600 μL solution, out of it 
3 μL was added to each well with 3 ml of PBS buffer containing permeabilized cultured 
cells. Plates were incubated in dark for 15 minutes. Cover slips with growing cultured 
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cells lying between cover slip and glass slide containing 50 μL of 10% glycerol. Slides 
were examined Carl Zeiss Axio Observer Z1, Microscope-Spinning Disc Confocal 
Scanning was done along XYZ plane z height was 15 μm and each section was scanned 
at 500 nm, to get the three dimensional picture. 
5.3. Results  
Premixed WST1 assay 
Viability in response to cytotoxic effect of nanoparticles on osteoblast cells 
measured by premixed WST1 assay. Cell survival can be assed in response to cytotoxic 
effect of nanoparticle and was first screened as a measure of mitochondrial 
dehydrogenase activity; cells treated with 1, 5, 10 15, 20 or 30 µg/ml concentration of 
ACB nanoparticles did not show any difference comparing to control cells as shown in 
Figure 5.1. However 20 and 30 µg/ml was significantly different comparing to control. 
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Figure 5.1. WST-1 Assay. ACB nanoparticles incubated with osteoblast cells for 24 
hours. 
 
LDH assay 
This assay is used to analyze the effects on cell growth inhibition and cell death; 
damaged cell membrane can cause the LDH to leak from the cells and is measured from 
supernatant. Positive control where maximum LDH is released in supernatant by lysing 
the cells, here in our study, Triton X-100 was used to lyse the cells as mentioned in 
protocol, a significant amount of LDH was released at 20 µg/ml concentration of ACB 
nanoparticles as shown in figure 5.2. These results also confer the results of WST1 assay 
where 20 µg/ml was also toxic. From 1 to 15 µg/ml concentration of ACB nanoparticles 
did not show any difference comparing to control group. 
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Figure 5.2. Cell Viability and toxicity assay. LDH assay by measuring LDH release from 
osteoblast cells in cell culture media of osteoblast cells treated with ACB nanoparticles. 
 
Oxidative stress  
Oxidative stress was a measure of reduced glutathione, protein carbonyl content 
and catalase activity. Oxidative stress could be measured by elevated or decreased levels 
of reduced GSH, If the concentration of free radicals generated exceed to reduced GSH 
molecules that will result in overall reduction in reduced glutathione and is considered as 
oxidative stress generated by ROS species, however an elevated level of reduced GSH in 
treated cells could be mild stress where ROS species are lesser than reduced GSH 
molecules, that elicits feedback cellular response and generates more reduced glutathione 
to protect cellular compartment from oxidative stress damage. 
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Reduced glutathione was measured from non-treated and treated cells as 
described in methods. ACB nanoparticles with concentrations of 1, 5, 10, and 15 µg/ml 
did not show any difference comparing to non-treated cells as shown in figure 5.3. 
However 20 and 30 µg/ml concentration was discontinued in the experiment because of 
toxicity observed in proliferation assay. Reduced glutathione concentration was 
normalized with total protein extract obtained from osteoblast cells.  
 
 
 
Figure 5.3. GSH assay. Measured reduced GSH concentration in ACB nanoparticles 
treated Osteoblast cells for 24 hour. 
 
Protein carbonyl content is a measure of oxidation of proteins and in this 
experiment following concentrations 1, 5, 10 and 15 µg/ml concentration of nanoparticles 
did not show any difference comparing to non-treated cells but 15 µg/ml was considered 
as toxic dose and was statistically significant comparing to control as shown in figure 5.4 
upper panel. Catalase activity was also measured for the same protein extract which was 
used for glutathione and protein carbonyl content. Catalase enzyme is ubiquitous enzyme 
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that is present in most aerobic cells. Catalase (CAT) is involved in detoxification of 
hydrogen peroxide, a reactive oxygen species (ROS), which is toxic product of both 
normal aerobic metabolism and pathogenic ROS production. This enzyme catalyzes the 
conversion of two molecules of hydrogen peroxide to molecular oxygen and two 
molecules of oxygen (catalytic activity). CAT also demonstrates peroxidatic activity, in 
which low molecular weight alcohols can serve as electron donors.   The nanoparticles 
concentrations 1, 5, 10 and 15 µg/ml was non-significant using student t-test comparing 
to control group as shown in figure 5.4 lower panel, although catalytic activity of 10 and 
15 µg/ml was suspected might have toxicity because the catalase activity difference was 
by 3 nmoles comparing to control group but statistically was non-significant with  p value 
= 0.162 and 0.152 for 10 and 15 µg/ml concentration respectively. 
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Figure 5.4. Protein carbonyl and Catalase assay. Upper figure shows Protein carbonyl  
content of ACB nanoparticles treated osteoblast cells for 24 hour and lower figure shows 
catalase activity of ACB nanoparticles treated osteoblast cells for 24 hour. 
  
Superoxide dismutases (SODs) are metalloenzymes that catalyze the dismutation 
of the superoxide anion to molecular oxygen and hydrogen peroxide and form a crucial 
part of cellular antioxidant defense mechanism. In human three forms of SOD: cytosolic 
Cu/Zn-SOD, Mitochondrial Mn-SOD, and extracellular SOD, in this assay all three 
SODs are measured as total SOD activity. 
64 
 
SOD activity was measured after treating osteoblast cells with nanoparticles for 
15 hours or 48 hours with different concentrations of nanoparticles as shown in Figure 
5.5. Standard curve was generated from the designed experiment to obtain final results.  
In 24 hr. incubation of osteoblast cells with  nanoparticles at different concentrations such 
as  1, 5, 10, 15 and 20 µg/ml,  there was no significant change observed  in SOD activity 
comparing to control group up to 15 µg/ml of ACB nanoparticle concentration, however 
at 20 µg/ml the SOD activity was slightly higher comparing to control and student T test 
was performed where p value was ≤ 0.05 and showed statistically significant difference 
for 20 µg/ml. which indicated the higher activity of superoxide dismutase within the 
intracellular environment possibly because of Superoxide radicals generated by 
nanoparticles, and keeps the superoxide radicals low to prevent cells from oxidative 
stress. This protective mechanism of SOD may also be responsible for lowering the 
toxicity of metallic nanoparticles from further damage.  
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BODIPY® 581/591 undecanoic acid can be used to detect reactive oxygen species 
(ROS) in cells and membranes. Oxidation of the polyunsaturated butadienyl portion of 
the dye results in a shift of the fluorescence emission peak from ~590 nm to ~ 510 nm. 
Ratio-fluorescence of C11-BODIPY 581/591   data was obtained and normalized to percent 
of emission of fluorescence as mentioned earlier in protocol. We did not observe any 
significant changes in emission spectra of groups treated with ACB nanoparticles 
comparing to non-treated group control, however at concentration 20 µg/ml there was 
10% loss of emission of red fluorescence which indicates oxidation of lipids in 
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Figure 5.5. SOD Assay. SOD activity of osteoblast cells treated with ACB 
nanoparticles for 24 hours in middle panel of the graph and Lower panel of graph 
shows the SOD activity for 48 hours treatment of ACB nanoparticles. Upper panel of 
graph represents standard curve. 
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membrane and same time there was gain of 13.5% of green fluorescence as shown in 
figure 5.6. This emission loss and gain corresponds to oxidation of lipids in the 
membrane. However it cannot be specified which group of lipids is oxidized; this assay 
can quantify whole lipids within the cell membrane.  
 
  
 
 
 
 
 
 
 
 
  
C11-BODIPY 581/591
CT
RL 1 5 10 15 20
5 m
M 
H2
O2
10
 m
M 
H2
O2
0
50
100
Ex/Em 570/591
EX/Em 500/515
Pe
rc
en
ta
ge
 R
.F
.U
Figure 5.6. Lipid oxidation Assay.  Cell membranes of osteoblasts stained by C11-
BODIPY 581/591  after treating with ACB nanoparticles for 24 hours. 
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Confocal results  
The fate of internalized bacteria was enumerated as live or dead for green or red 
color respectively by confocal microscopy as shown in figure 5.7. Control Group 1 was 
neither infected nor treated with antibiotic or nanoparticles and did not show any sign of 
infection in terms of dense green or red sports. Group 2 S. aureus infected, was 
observed as S. aureus infected as green spots and was not treated with gentamicin or 
ACB nanoparticles hence no dead bacteria were expected and the population of 
internalized bacteria was high comparing to treated groups. Group 3, S. aureus infected 
and treated with 200 µg/ml of gentamicin, live S. aureus were seen as green spots and 
few dead bacteria 2-3 in number per each cell were dead because in 48 hour incubation 
gentamicin may get permeabilized at very low concentration can cause death of bacteria, 
moreover dead bacteria can also be internalized as efficiently as live bacteria. Overall the 
bacterial population was reduced in gentamicin treated group, gentamicin in media keeps 
continuously killing bacteria coming out of cells, bacterial cells transport in and out 
spontaneously as a result also leads to reduction in infection. Group 4 infected with S. 
aureus and treated with Ag-Cu-B (ACB) nanoparticles, red spots seen were dead S. 
aureus and few green which were considered alive, also the total number of bacteria (live 
and dead) were very few comparing to gentamicin treated group. This experiment also 
confirmed the antimicrobial activity of ACB nanoparticles at intracellular level and also 
supports the experiment of invasion assay for antimicrobial activity in internalized S. 
aureus.  
 
68 
 
 CONTROL S. AUREUS INFECTED 
GENTAMICIN NANOPARTICLES TREATED 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4 Conclusion  
The antimicrobial efficacy and cellular toxicity associated with ACL and ACB 
nanoparticles is presented. It was found that ACL particles were more efficient 
antimicrobial nanoparticles comparing to ACB, however the toxicity associated with 
ACL particles was close to or 10 µg/ml which was shown by catalase activity. In 
comparison, the significant toxicity for ACB nanoparticles was observed at 20µg/ml by 
WST1 and LDH assay, only protein carbonyl content for ACB nanoparticles was 
significant at 15 µg/ml which was analyzed as very low stress comparing to ACL 
Figure 5.7. Confocal studies. Osteoblast cells invaded by S. aureus and treated with 
Gentamicin or ACB nanoparticles. Upper left panel shows control group and upper 
right panel shows osteoblast cells infected with S. aureus without treatment, Lower 
left panel shows infected osteoblast cells treated with Gentamicin and Lower left 
panel shows infected Osteoblast cells treated with 1 µg/ml ACB nanoparticles. 
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nanoparticles. Efficacy of ACB nanoparticles were also shown my confocal studies 
where 1 µg/ml concentration showed significant reduction in internalized CFU.  
 Based on the antimicrobial efficiency and minimum toxicity of ACB 
nanoparticles, this study suggested use of animal study to explore the toxicity in in-vivo 
in which similar dose 1 mg/kg of b. wt. was parallel to 1 µg/ml used in in-vitro studies.  
However 2 mg/kg of b. wt. was also studied as higher dose.  
This study has shown the efficacy of ACB particles to clear internalized infection 
and encouraged the development of osteomyelitis model in mouse to evaluate the 
efficiency of antimicrobial activity in in-vivo.  
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CHAPTER VI 
TOXICITY IN ANIMAL STUDIES 
Based on the antimicrobial potential of ACB nanoparticles to fight against 
internalized infection at in-vitro study, animal toxicity experiments were conducted to 
predict the safe dose that can be used in in-vivo study. Silver nanoparticles distribution in 
vital organs have been reported among rats, mouse, and rabbit [86]. It was shown that the 
silver nanoparticles are excreted from the body. The silver nanoparticles dose varied from 
9 mg/kg of body weight to 90 mg/kg of body weight for 28 days. Silver clearance was 
studied from post 28 days for 1 week or 8 weeks, it was found with time silver was 
cleared from tissues except the concentration of silver in brain and testis was high [86]. 
However the silver ions released from nanoparticles caused biological activity [87, 88]. 
ACB nanoparticles are different than early suggested nanoparticle by composition which 
are composed of three elements as discussed, besides silver-copper antimicrobial activity, 
it is believed that boron helps in slowing the release of ions which may also help in 
reducing the toxicity and long term antimicrobial effect. Hence, it is suspected that ACB 
nanoparticles might have less toxicity compared to silver alone nanoparticles where 
release of silver ions is very random and fast. 
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6.1. Animal Use  
All experiments were conducted at the Animal Care Facilities of Faculty of 
Medicine and Health Sciences at the University of United Arab Emirates at Al Ain UAE.  
The animal facility provides for, and is in charge of care of, the laboratory animals in 
accordance with all policies of United Arab Emirates that are similar to USDA and US 
Public Health Service.  A Surgeon, professor of Anatomy (Dr. Eric Brown), and certified 
animal care support personnel were available and were able to provide professional 
veterinary, surgical and animal care services in support of investigators’ animal use 
studies.  Animal welfare is closely monitored by a committee appointed by the University 
Chancellor. 
6.2. Methods And Materials 
All Animals studies were performed under university committee for animal 
resources approved protocols. After i.p. injections of nanoparticles, animals were 
returned to standard isolator cages. B-6 mice (20 g) mice with 7 mice in each group, one 
group were injected i.p. with ½ ml of 40 μg/ml (1 mg/kg of body weight) of ACB 
nanoparticles (equivalent of 1 ml of 20 μg/ml localized injection) and the second group 
was injected i.p with ½ ml of 80 µg/ml (2 mg/kg of body weight) with ACB 
nanoparticles (equivalent of 1 ml of 40 μg/ml localized injection). Following the 
nanoparticles injection by 4 hours and 24 hours blood was collected for platelets, white 
blood cells and red blood cells count and hemoglobin, enzyme analysis (AST, ALT, 
LDH, BUN, Creatinine). Group of mice with 4 hour and 24 hour post subcutaneous 
injection of nanoparticles were sacrificed and vital organs including; brain, heart, lungs, 
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kidney and liver were dissected out and fixed in 4% formalin, post fixation portion of 
each vital organ was lyophilized and 500 mg of each organ weighed out and digested in 
5% nitric acid overnight and homogenized. Aliquot of homogenate was diluted in 5% 
nitric acid serial dilutions were made for use of ICP-ES-700 spectrophotometer for 
estimation of silver, copper and boron elements. 
6.3. Results  
In-vivo toxicity was primarily screened from blood profile as shown in figure 6.1; 
to check the immunotoxicity. Platelet count (PLTS), red blood cells (RBC), white blood 
cell count (WBC), hematocrit (HCT) and hemoglobin (Hgb) value. Treated groups of 
mice were non-significant compared to control as shown in figure 6.1. All the values 
were observed in the normal range as control with no significant change.  
Blood biochemical analysis was carried out for 4 hour and 24 hour post nanoparticle 
injection on the groups with low dose (1 mg/kg of body weight) as shown in figure 6.2. 
There was no change in any enzyme tested compared to control. AST and ALT is 
indicative of liver injury. Theses enzymes in all groups of treated or non-treated in the 
normal range, signifying there was no indication of acute hepatotoxicity. LDH and BUN 
which are markers for tissue damage and renal function respectively and both were also 
in the normal range for treated and non-treated group. Another group of mice for 4 hour 
post nanoparticle injection with high dose (2 mg/kg of body weight) as shown in figure 
6.3 for blood profile, there was no change observed compared to control group. However, 
the group with high dose 2 mg/kg of body weight, post 4 hour injection; liver enzymes 
(AST and ALT) were significantly different than control group, whereas LDH, BUN and 
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creatinine was normal as shown in figure 6.4. Group with 1 mg/kg of body weight 
injection via i.p. post 4 hour and 24 hour injection the distribution of silver, copper and 
boron is as shown in Figure 6.5. In 4 hour treatment the amount of nanoparticles in vital 
organs was increased in 24 hour incubation which was indication that the ACB 
nanoparticles takes longer than 4 hour to be distributed in organs and tissues, while as 
boron was very less in 24 hr compared to 4 hr and was believed may be due to its low 
concentration compared to silver or copper. With 2 mg/kg of body weight the 
nanoparticles was slightly higher in liver comparing to other organs as shown in figure 
6.6. and measured for 4 hr only.  
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Figure 6.1. Blood analysis of B-6 mice. Groups treated post 4 hour or 24 hour with 
nanoparticle injection or saline. 
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Figure 6.2. Enzyme analysis of B-6 mice. Groups treated with ACB nanoparticle 1 
mg/Kg body weight or saline via i.p. Left panel shows post 4 hour treatment analysis and 
right panel shows post 24 hour treatment analysis.  
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Figure 6.3. Blood profile of B-6 mice. Analysis done post 4 hour treatment with 2 mg/kg 
of body or saline via i.p. 
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Figure 6.4. Enzyme analyses for 2 mg/kg of body weight. Treated and non-treated groups 
were analyzed post 4 hour of nanoparticle injection or saline via i.p. 
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Figure 6.5. Elemental distribution for 1 mg/kg b.wt. of nanocidals. Groups injected with 
ACB nanocidals via i.p. were analyzed post 4 hour or 24 hour treatment.  
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Figure 6.6. Elemental distribution for 2 mg/kg of b. wt. of nanocidals. B6 mice groups 
injected with nanocidals were analyzed post 4 hour treatment.  
 
6.4 Discussion 
In-vivo experiments were carried in this study to detect the toxic dose among 
animals. It was found that nanoparticles administered via i.p 1 or 2 mg/kg of body weight 
did not show any response in blood profile comparing to non-treated post 4 or 24 hrs. of 
i.p. administration which signifies that there was no non-specific immune response.  The 
liver enzymes aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) 
which are biomarkers for liver damage were studied. Lactate dehydrogenase (LDH) 
enzyme in glycolysis used as biomarker for tissue damage. Blood Urea nitrogen (BUN) 
as a measure of renal function. For groups treated with 1 mg/kg of body weight there was 
no significant change was seen in AST, ALT, LDH, and BUN compared to non-treated 
groups of mice, which is signifying that there may be no acute hepatotoxicity or renal 
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toxicity associated and neither any tissue damage within the body. However in groups 
treated with 2 mg/kg of body weight, there was significant changes observed in liver 
enzyme ALT and LDH, this sign may be considered as toxic dose and was speculated 
that ACB nanoparticles or ions released may accumulate in liver at certain concentration. 
In previous study, it was reported that mice were exposed to silver for 28 days by oral 
administration, with 0.25, 0.5 and 1 mg/kg of body weight only, 1 mg/kg showed 
significant changes in liver enzymes [89]. In another study, rats were exposed to 90 or 9 
mg/kg of body weight with nano-silver or sliver salts for 28 days and did not observe any 
significant changes in liver enzymes, and 8 weeks post dosing silver was cleared from 
most of organs except from brain tissues where concentration was higher compared to 
other organs [86]. In these studies, it is not understood the reason for 1 or 90 mg/kg of 
body weight being nontoxic or toxic respectively, It is concluded that animals has 
tolerance for silver and it varies for other types of animals.  
However, 2 mg/kg of body weight did show elevation in liver enzymes but such 
changes in liver enzyme concentration could be reversible. More studies are required to 
explain the toxicity from the silver nanoparticles or ionic silver. The fate of nanoparticles 
after injection in mouse is not studied well but the assumption is that once they reach to 
tissues, nanoparticles can be digested into ions because of lactic acid present in tissue, as 
mentioned elsewhere in paper lactic acid was used to reduce the size of nanoparticles, in 
humans most of lactic acid is produced from red blood cells and muscles [90]. Moreover, 
the distribution of released ions of silver, copper and boron in mice was examined by 
ICP-ES spectrophotometer and our data suggested these ions are excreted from the body 
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with time and it takes more than 4 hours to be absorbed from i.p. for its distribution via 
blood to rest of the body tissues or organs.  Mice with toxic dose, nanoparticle 
accumulation was higher in liver that could be another reason for significant changes in 
liver enzymes and it was studied only for two experimental groups 4 hours and 24 hours. 
The experiment was designed to evaluate the rapid distribution of nanoparticles or ions 
released from nanoparticles so the data cannot be assumed as total retention of 
nanoparticles by organs or tissues. It is observed that in 4 hours all vital organs has lesser 
silver or copper concentration comparing to 24 hr, from this data it is concluded that 4 hr 
may be less time to be absorbed 100% of the loaded particles and may require more than 
4 hours. Although the boron behavior was opposite to that of silver and copper, higher 
concentration at 4 hr and less in 24 hr, this may be due to the fact that boron is present in 
trace amounts compared to silver or copper. Further investigation is required with groups 
more than 2 days to 7 days of post i.p. Injection for elemental analysis and equally if any 
immunogenic response is elicited also need to investigated.  
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 CHAPTER VII 
OSTEOMYELITIS ANIMAL MODEL 
Osteomyelitis animal model was first attempted by Rodet 1885, followed by 
Lexer 1894 where they simply injected attenuated S. aureus into rabbits and determined 
that it is impossible to develop medullary infection by intravenous injection of S. aureus 
alone [91]. Only few works were followed in first half of 19th century by Starr in 1922 
and Haldeman in 1934 and Thompson and Dudos in 1938 where they inject S. aureus 
directly or indirectly into the bone, osteomyelitis lesions were observed and did not 
mimic human infection conditions [92]. Several years latter chronic osteomyelitis model 
was reported by Scheman et al in 1941 [93] by using rabbits, S. aureus and sodium 
morhuate was directly injected into the tibia metaphysis. This rabbit model was further 
studied and nurtured by Nordon in 1970 [94] and Andriole et al in 1973 [95]. From 1960 
up to 1997 several animal models were developed including rats, dogs, chicken, guinea 
pigs and very few models of mice.  
7.1. Mouse Tibial Models 
First mouse tibial model was demonstrated by Ueno in 1974 and followed by 
numerous scientists. A 3 –mm long briaded silk suture with size 3-0 was soaked in S. 
aureus and P. aeruginosa suspensions and this piece of infected thread was inserted in 
needle-created hole at tibial metaphysis of mice. This model was reported as successful 
model of osteo-myelitis and resembles as human osteomyelitis. 
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In 1979 an excellent mouse hematogenous model was reported by Kobayakawa 
and investigated the effect of foreign body (3mm long silk thread size 5-0) introduction in 
to the proximal tibial metaphysis. They observed that  almost all bones were infected first 
and latter significant proliferation was in femur and tibia. They believe thread has 
significant effect in retention of bacteria in bone and two weeks post inoculation they also 
reported that thread exerts no effect in on distribution and proliferation except the 
retention of bacteria in bone. Chadha et al and Yoon et al reported another model of 
osteomyelitis by involving upper epiphyseal injuries and intravenous injection of 
bacteria. They observed swelling and warmth of limb and abscess formation was evident 
in proximal tibia. They also showed histological studies for the evidence of osteomyelitis 
and evidence of recovery of S. aureus from infection site.     
 Common routes of inoculation  
Three routes have been reported:  
1. Local inoculation to the bone cavity.  
2. Local inoculation through nutrient arteries and systemic infection through i.v.   
3. Local inoculation of bacterial suspension by whole drilled in bone.  
An alternative method is by implanting foreign material with infection that was 
recently developed.  S. aureus strain was incubated with stainless steel and mouse tibia 
bone was drilled by 18g needle and infected pin was inserted and sides were bent. S 
aureus strain they used was XEN-36 a bioluminescent bacteria where the progression of 
infection was monitored by Xenogen IVIS camera system.  Table 3.1 summarizes the 
different routs to induce osteomyelitis in animals [92]  
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Table 7.1. Animal and bacterial species for inducing experimental Osteomyelitis. 
Animal Bacteria Site  Implant 
Chicken S. aureus / E. coli i.v.  
Guinea pig S. aureus Femur IM pin 
Rabbit S. aureus Tibia  
Dog 
 
S. aureus Tibia  
Sheep S. aureus Tibia  
Goat S. aureus Tibia Bone wax 
Rat S. aureus Tibia IM K-wire 
Mouse S. aureus Tibia Silk thread 
 
Mouse S. aureus Tibia Transcortical pin 
 
7.2. Methods And Material In Osteomyelitis Mouse Model  (BALB/C) 
In this study BALB/c mouse was used to generate osteomyelitis in left tibia bone 
infected with S. aureus with the aid of braided silk suture. The formation of osteomyelitis 
was followed by injection of ACB particles. Osteotomy of tibia was performed under aid 
of anesthetics Xylazine 100mg/kg of body weight and Ketamine 10 mg/kg of body 
weight.    
S.aureus XEN-36 strain which was derived from the parental strain S. aureus 
ATCC 49525, stock was stored in glycerol at -80°C. This kanamycin resistant XEN 36 
was streaked on tryptic soy agar plate and recommended dose of kanamycin was 200 
µg/ml. Bacterial colonies grown on T-soy agar plate were inoculated into 5 ml of T-soy 
broth and cultured stationary overnight with aeration. The overnight grown bacterial 
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culture was then sub-cultured at 1:5 ratio and grown to mid-log phase for another 2 hours 
with shaking at 200 rpm and was stopped when O.D. reached to 0.5 at 600 nm. 
7.2.1. Confirmation of CFU’s with O.D 0.5 at 600 nm 
With 0.5 O.D. at 600 nm, bacterial cells in 5 ml of T-soy broth were harvested by 
centrifugation at 4000 rpm for 20 minutes and the pellet was re-suspended in 5 ml of PBS 
pH 7.4. Serial dilutions were performed in sterile PBS and 100 µl aliquots were plated on 
T-soy agar plates with 200 µg/ml kanamycin. With bacterial colony forming units 
(CFU’s) were enumerated after overnight incubation at 37°C. Moreover selected colonies 
were dissolved in PBS buffer with pH 7.4 and bioluminescence was measured using 
Perkin Elmer Illuminometer to confirm the XEN-36 strain besides kanamycin selection. 
7.2.2. XEN-36- S. aureus growth on braided silk suture  
Braided silk suture 0-3 size reverse cutting edge was purchased from SMI, 
REF.NO. 8151516, LOT NO. 110623 was immersed in a culture of XEN-36 in T-soy 
broth with 200 µg/ml of kanamycin with 0.5 O.D. at 600 nm which corresponds to 7×107 
CFU’ per ml. Silk suture was incubated in bacterial broth for 45 minutes or 150 minutes. 
After incubation silk suture was gently washed in PBS and a piece of 2 cm was cut with 
the help of sterile scissor and 2 cm length was further chopped into small pieces by sterile 
scissor in 1 ml of PBS and followed by homogenization by tissue homogenizer. Serial 
dilutions of silk homogenate were performed in sterile PBS and 100 µl was plated in T-
soy agar plates with kanamycin. Number of CFU’s were enumerated after overnight 
grown at 37 °C in incubator.  
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7.3. Methods And Material Of Osteotomy 
8-12 week old BALB/c female mice were anesthetized with a combination of 
Xylazine 10 mg/kg of body Wt.) and ketamine (100 mg/kg of body wt). Xylazine and 
Ketamine ratio were made in a final volume of 10 ml PBS. 0.1 ml of combined Xylazine 
and Ketamine was administered as single intra-peritoneal injection (i.p.) After thorough 
cleaning the whole of the lower limb with 70% ethanol the shin was sectioned with a 
scalpel blade to expose the whole tibia. The muscles posterior to the tibia were retracted 
to expose the posterior aspect of the bone, care being taken not to fracture the fibula. By 
means of a drilling machine (Cole palmer), sterile steel drill bit of tip diameter 0.25 mm 
(size) was designed in Mechanical Engineering Department at the United Arab Emirates 
University, a hole of size 0.5-1.0 mm was made immediately below the tibial tubercle of 
mouse. The bone was drilled from posterior to the anterior aspects of the bone. Sterile 
braided silk suture or braided silk suture with XEN-36-S. aureus was passed through the 
hole of tibia bone and silk suture was stabilized by putting double knot, and sides were 
cut close to knot, approximately 1.5 cm of thread was used for each bone. Stabilizing the 
knot is important; mouse usually bites his stiches and displaces the tissue that could 
remove the silk suture from the hole.  Prior to stitching of skin, exposed area of bone and 
surrounding tissue was wiped with 70% ethanol that prevented the systemic or myositis 
infection. Mice recovery from anesthesia was observed after 2 hours and were returned to 
fresh cages. After surgery mice were fed normally for 6 days, on the sixth day mice were 
euthanized via inhalation carbon dioxide and were used for analysis. The steps of surgery 
are as shown in figure 7.1. 
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Mouse processing and homogenization of tibia bone 
Post 5th day of surgery, mice were sacrificed, immediately lower abdomen was 
operated by one horizontal incision and two vertical incisions from either side of 
abdomen, intestines were pushed on side and inferior vena-cava was used for blood 
collection. A piece of liver and whole spleen was collected and weighed. From the left 
leg tibia bone was isolated from the tissue, care was taken not to break the bone and 
tissues attached to the bone were separated in order to get clean tibia free from tissues as 
shown in figure 7.2. Site of surgery was identified and tibia bone was weighed. After 
weighing, bone was added in 1 ml of sterile PBS buffer pH 7.4 and placed in a 35 mm 
petri-dish and was chopped with the help of sterile scissor. 1ml of bone soup was 
transferred in 2 ml Pyrex tube for homogenization including the chopped bone pieces 
with the help of forceps and followed by homogenization. Liver and spleen tissues after 
weighing were directly placed in 1ml of PBS buffer pH 7.4 for homogenization in 2 ml 
Pyrex tubes. After homogenization of tissues, samples were serially diluted by 10 fold in 
sterile PBS and 100 µl aliquot was placed on T-soy agar plate containing 200 µg/ml of 
kanamycin.  Remaining  of the homogenized tissue was utilized for other biochemical 
analysis and were stored in -80ºC. 
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Figure 7.1. Representation of surgical procedures. 1 shows the incubation of silk suture 
with s. aureus bacteria in TSB broth, 2 and 3 shows drilling tibia bone with 0.25 mm drill 
bit, 4 and 5 shows the drilled hole in tibia without damaging surrounding tissues, 6 shows 
the infected silk suture in bone , 7 and 8 shows suture of skin of leg.  
  
1 2 
3 4 
5 6 
7 8 
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7.4. Experiments 
7.4.1. 1 mg/kg b. wt. of ACB nanocidals via i.v injection for treatment of 
osteomyelitis induced by XEN-36-S. aureus  
Post 5th day of surgery, two groups were selected as, Control group with n = 6 
mice and treated group of n = 10 mice.  The treated group received ACB dose of 1 mg/kg 
b.wt via intravenous (I.V.) through dorsal vein of tail. Control group was given saline of 
equal volume like control group via i.v. through dorsal vein of tail. Prior to i.v. injection 
mouse was kept under IR-light to warm up the tail for dilation of veins.  After receiving 
i.v. injection either ACB or saline mice were transferred to fresh cages. After 24 hours of 
treatment mice were sacrificed and tissues of bone, live and spleen were weighed and 
homogenized in 1 ml of PBS. Blood was collected from inferior vena cava. Serial 
C A B 
Figure 7.2 Bone Processing. Tibia bone with silk suture thread attached (A), 
Tibia bone cleaned (B), Focused drilled hole in tibia 
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dilutions of tissues were performed in sterile PBS buffer and 100 µl aliquots were 
pipetted in T-soy agar plates with 200 µg/ml. CFU’s were enumerated after overnight 
incubation at 37°C. 
7.4.2. 0.1 mg/kg b. wt. of ACB nanocidals via i.v injection for treatment of 
osteomyelitis induced by XEN-36-S. aureus   
Two groups each with 5 mice. Post 5th day of infection, treated group received 
ACB nanocidals treatment with 0.1 mg/kg b. wt and control group received saline alone. 
After 24 hours of treatment mice were sacrificed, blood, liver, bone and spleen was 
collected. Tissues were homogenized in 1ml of PBS buffer pH 7.4 and aliquots from each 
sample were spread on kanamycin treated T. soy agar plate. CFU’s were enumerated 
after overnight incubation at 37 degree C. 
7.4.3. 0.5 mg/kg b. wt. of ACB nanocidals via i.v injection for treatment of 
osteomyelitis induced by XEN-36-S. aureus   
This experiment was similar to experiment 2 except the dose was 0.5 mg/kg b.wt. 
and processing was same as above experiment. CFU’s were enumerated from each tissue. 
7.4.4. 1 mg/kg b. wt. of ACB nanocidals via i.m. near injection site for treatment of 
osteomyelitis induced by XEN-36-S. aureus  
Osteomyelitis infection was developed in each group as discussed as earlier. Post 
5th day of surgery two groups were selected, with 5 mice in each group, one control group 
was treated with saline alone and other group was treated with ACB 1 mg/kg b.wt. After 
24 hours of treatment mice were sacrificed, blood, liver, spleen and tibia bone was 
obtained from each mouse and were processed. Aliquot of each tissue homogenate was 
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serially diluted and 100 µl was spread on T. soy agar plate with 200 µg/ml of kanamycin.  
After overnight incubation of culture plates, CFU’s were enumerated and normalized per 
gram of tissue.  
7.4.5. Antibiotic Co-trimoxazole and negative control of ACB nanocidals for 
treatment of osteomyelitis induced by XEN-36-S. aureus 
In this study three groups each with five mice and all surgeries were performed 
same day to induce infection in tibia. Post 5th day of surgery, control group received 
saline alone via i.v. and antibiotic treated group received trimethoprim/sulfamethoxazole 
via drinking water for 24 hours and negative nanoparticles group received iron oxide 
nanoparticles 1 mg/kg of b. wt. via i.v. The average size of iron oxide nanoparticles was 
20 nm and were synthesized in lab.  After 24 hour of treatment mice were sacrificed and 
tissues were collected. Sample processing was done similar to as explained for other 
experiments. CFU’s were enumerated from each tissue. 
 7.4.6. Survival – post ACB nanocidals treatment of osteomyelitis induced by XEN-
36-S. aureus 
In this study 15 mice were grouped into three groups, 1st group – control group 
received saline every once a week, 2nd group – treated with ACB 1 mg/kg b. wt. as single 
dose and 3rd group – treated with ACB 1 mg /kg b. wt. as multiple doses, each dose once 
in a week for three months. Every day cages were inspected to evaluate the morbidity or 
death of mouse. 
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7.5. Results And Discussion 
A prophylactic model was developed to treat osteomyelitis using nanocidals. 
However, in reported models have associated systemic infection and did not study 
antimicrobial activity by silver or silver alloy nanoparticles. The model developed in this 
study, was highly localized and without any sign of hematogenous infection nor  any 
colonies from liver or spleen were found. The model is similar to Ueno et al 1974 model 
which was the first tibial mouse model reported except the modifications that machine to 
drill hole and drill bit size at the tip was 0.25 mm, that made surgery very easy and 
reproducible. The upper wider part of tibia just below the tubercle is just few millimeters 
wide then bone tappers until distal end. The outer layer of the calcified bone makes it stiff 
and fragile that was the reason rabbit and rat tibial osteomyelitis model are developed 
well in comparison to mouse model.  Attempt to induce a hole in tibia with help of 25g or 
18g needle as reported in literature was associated with multiples difficulties like high 
risk of fractures, while holding distal end of tibia there was chance to damage fibula, also 
induced damage to muscles and surrounding tissues. It needs manually more pressure on 
needle that caused fractures. In an experiment, a group of 5 mice was used in which 2 
mice had fractures in tibia bone and other 3 developed necrosis of foot post ten days of 
surgery. Leg is highly vascularized if vessels are cut during surgery that will lead to 
necrosis of bone or associated tissue, especially posterior tibial artery that supplies 
posterior compartments of leg and plantar surface of foot. In this study, the tibia bone 
was exposed and retracted gently gastrocnemius muscles and soleus muscles to expose 
posterior tibia. The tibia bone was drilled from posterior to anterior side to prevent 
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damage of posterior tibial artery; this technique has major advantage of reducing damage 
to surrounding parts and drilling bone at a desired place with precision. The number of 
bacteria XEN-36 corresponding to OD value was estimated. It was found that with 0.5 
O.D. at 600 nm is approximately equal to 6.45 ×107 CFU’s per ml as shown in figure 7.3 
panel A, and the O.D. value was fixed for all experiments to incubate the silk suture for 
45 minutes, furthermore the number of XEN-36 bacteria per cm of silk suture was 
enumerated. It was found that 1 ×104  CFU’s/ml in 45 minutes incubation and 150 
minutes as 5.1 ×106 CFU’s per cm as shown in figure 7.3 panel B.  
 In the surgical procedure the infected silk suture utilized was 1.5 cm in length 
including the knot which corresponds to approximately 1.5.×106 CFU’s, however a part 
of thread as tiny knot was outside the drilled hole, so the number of CFU’s was average  
between 1 ×105 to 1 ×106  CFU that were utilized for development of infection. 
Experiment 1, in this study, post 5th day of surgery 1mg/kg of body wt. of 
nanocidals were given through intravenous (i.v.) as shown in figure 7.4. The aim for i.v. 
injection was to ensure it reaches to all parts of the body in short time in order to observe 
antimicrobial activity in 24 hr, however in this method nanocidals can be excreted at 
faster rate.  
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Figure 7.3. Growth of XEN-36 strain. Growth in TSB media (A), number of XEN-36 
bacteria on silk suture (B). 
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Figure 7.4. Osteomyelitic mice treated with nanocidals. CFU’s present in tibia bone were 
enumerated post 24 hour treatment. 
 
Data shown in Figure 7.4, represent the growth of XEN 36 in tibia bone and with 
the treatment of nanocidals for 24 hours a significant reduction in CFU’s was observed 
comparing to sham group by 2 logs down, p-value ˂ 0.0012 and no growth was positive 
for blood, spleen, and liver. p-value was obtained by Mann whitney test. This data 
supported our following clims: (1) this method of inducing osteomyelitis will be a 
localized infection and does not show systemic infection. (2) nanocidals were effective 
antimicrobial agent in in-vivo. 
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Two more experiments were carried out in which low doses were used as shown 
in figure 7.5.  ACB nanocidals with 0.1 and 0.5 mg/kg of b. wt. was injected i.v. and  It 
was found that CFU reduction by 0.69 logs down by using 0.5 mg/kg of b. wt. comparing 
to control group and statistically was non-significant with p-value 0.2, in figure 7.5- panel 
A and while in ACB nanocidals with 0.1 mg/kg of b. wt. there was 0.355 logs down and 
statistically non-significant with p-value 1 in figure 7.5- panel B. These findings suggest 
that ACB with 1 mg/kg b. wt has potential to reduce infection by more than 50% with 
single dose, and data for 0.5 and 0.1 mg/kg of b. wt. showed a pattern in reduction like 
0.69 logs and 0.355 logs respectively, which also showed that antimicrobial activity was 
proportional to the concentration of dose, by increasing the concentration of ACB 
nanocidals the antimicrobial activity was increased proportionally.   
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Figure 7.5.   Low dose of ACB Nanocidals. Treatment with 0.5 mg/Kg of b. wt. (A)  
and 0.1 mg/Kg of b. wt. (B). 
  
In this study the effect of localized delivery of ACB nanocidals was evaluated. 
ACB particles were injected locally near the infection site as a model for local delivery as 
shown in figure 7.6. panel-A. The aim of this experiment was to find the efficacy of ACB 
if given near infection site via intra-muscular (i.m.). It was found that in 24 hours post 
injection of ACB there was 1.8 logs reduction with p-value = 0.0121, however it was 
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clear from the data that i.v. delivery or local delivery were equally effective. This data 
provides additional insight that these ACB nanocidals can be delivered into the body 
either intravenous or intramuscular similar to antibiotics. Moreover infection was 
obviously in tibia bone so i.m. delivery near the infection site was not so accurate method 
of local delivery it may work better if injected directly in bone, which is as good to 
another surgery. While injecting ACB in i.m. the mice was anethetesized with xylazine 
and ketamine, believing that i.m. injection in gastrocnemius or soleus muscles is painful. 
Finally concluded that ACB nanocidals delivery via i.m. is also another route of delivery  
In the next round of surgery to induce osteomyelitis on 15 mice those were distributed in 
3 groups with 5 mice in each group , One group was used  for negative control for 
nanoparticles, considering they are not antimicrobial but are metallic nanoparticles (iron 
oxide), 2nd group was used for commercially available antibiotics which was provided by 
Prof. Basel K Ramadi, a faculty at United Arab Emirates University, as Co-trimoxazole 
with salt of trimethoprim/sulfamethoxazole which broad spectrum antibiotics. As shown 
in figure 7.6 panel-B, negative control of ACB nanocidals did not show any difference 
comparing to control group given saline alone, however antibiotics did not show any 
significant data statistically p-value = 0.1, but results obtained cannot be ignored if 
statistically non-significant it was found 0.8 logs down which is close to 25% reduction, 
dose of Co-trimoxazole antibiotic was 200 µg/ml. 
Animal survival studies were also conducted, another set of 15 mice ready post 5th 
day of surgery Group 1 control injected via i.v. saline only, Group 2 single dose of ACB 
nanocidals with 1 mg/kg of b. wt via i.v. Group 3 multiple dose of 1 mg/kg of body 
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weight once in every week via i.v. as shown in figure 7.7, here experiment was carried 
out for  16 weeks and no death of any mouse from any group occurred. Moreover no 
signs of morbidity or suppressed physical activities were observed, both the groups either 
single dose or multiple dose act similar to control group. This was encouraging data that 
these nanoparticles with multiple doses did not kill the animal; it is believed that the 
reason for successful 100% survival could be ACB are excreted from tissues with time at 
higher rate. Initially these particles are distributed everywhere in the body and shows 
short-term retention of nanoparticles. One of the studies has shown that for 28 days silver 
nanoparticles were given and up to 90 days almost all silver is excreted from the body 
except from testis and brain where retention was slightly higher.  
7.6. Reduced Glutathione Assay 
Glutathione a tripeptide is a most potent free radical scavenger found in our body 
and is almost found in all cells or tissues present in our body, it constitutes nearly 90% of 
all radical scavengers present in human body, as a result is widely used a known marker 
for oxidative stress.    
7.6.1. Methods and materials 
This assay was done similar to in vitro studies as Coleman et al.[83] homogenized 
tissue in Tris-EDTA buffer pH 8.8 was further diluted 50 folds in same buffer. 
Homogenized sample was centrifuged at 4000 rpm for 20 minutes at 4 degree C. 
supernatant was collected for GSH assay and total protein assay. Procedure for GSH was 
followed as discussed in chapter 2. Total protein estimation was done by BCA assay 
assay as mentioned elsewhere and its standard curve was generated by using bovine 
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serum albumin. Similarly for GSH assay Standard curve was generated from standard 
reduced L-glutathione.  
7.7. Results 
Groups of mice used in osteotomy experiments were used to measure the GSH  
levels.Group of mice treated with 1 mg/kg of b. wt. via i.m. and its control group treated 
with saline only were used for GSH assay as shown in figure 7.8, it was found that there 
was no significant difference in bone, liver and spleen, however in bone there was 30% 
increase in GSH level although test was non-significant but showed tendency to increase 
the GSH level, increasing or decreasing GSH level after treatment notifies the presence of 
oxidants in the tissue. Increase in GSH level is due to feedback mechanism where cellular 
GSH levels are consumed and expression of GSH increases to counter attack the presence 
of radicals. However, when the concentration of ACB accedes to GSH level, net 
intracellular GSH level drops down causing oxidative stress but that was not observed in 
this study.  GSH plays an important role in scavenging free radicals and protects cells 
from dying or aging. Here the results showed no significant difference by 1 mg/kg b. wt. 
exposure of ACB nanocidals comparing to control group. Similarly using ACB with 0.5 
mg/kg of b. wt, antibiotic trimol via drinking water, and negative control 1 mg/kg of b. wt 
of nanoparticles of iron oxide did not show any significant changes in GSH levels 
It is concluded from data that ACB up to 1 mg/kg of b. wt may be safe to use in animal 
studies for antimicrobial treatment. 
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Figure 7.6. Localized delivery. ACB nanocidals treated with 1mg/kg of b. wt via i.m. (A), 
negative control of ACB nanocidals via i.v. and antibiotic via drinking water.(B). 
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Figure 7.7. Mice survival. Groups of mice treated with ACB nanoparticles where orange 
color for single dose, green for multiple doses and red as control group treated with 
saline. 
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7.8. Histology Materials And Methods 
Groups of BALB/c mice treated with ACB nanoparticles, dose 1 mg/kg of b. wt. 
and control groups treated with saline only were euthanized after 24 hours of treatment. 
Liver, spleen and tibia bone were collected as mentioned earlier and were fixed in 
formalin 10% for overnight, bone was decalcified by treating tibia bone with 0.5 M 
EDTA in a PBS buffer and were kept overnight at room temperature. After 
decalcification, decalcified bone, Liver, and spleen were processed an embedded in 
parafilm. 4 µm thickness sections were cut and then were stained with hematoxylin and 
eosin stain.  
Figure 7.8. GSH Assay in-vivo study. Effect of nanocidals 1 mg/kg b. wt via i.v. (A). 
Effect of negative control Iron oxide 1 mg/Kg of b. wt and ACB nanoparticles 0.5 
mg/Kg of b. wt.(B) Effect of ACB nanoparticles administered locally (C). Effect of 
antibiotic Co-trimoxazole (D). 
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7.9. Results And Discussion 
To determine the proliferation of blood cells or inflammatory infiltrate and 
morphology of cells within the organs, BALB/c mice with S. aureus infected tibia bone 
by surgical procedure using braided silk suture as explained earlier in surgical procedure 
were treated with 1 mg/kg b.wt. or saline via intravenous injection though dorsal vein of 
tail. Histological slides were harvested from liver, spleen and tibia bone post 24 hour 
treatment. Liver and spleen slides did not show any difference in cell morphology 
comparing to control groups neither was any significant infiltration of neutrophils seen in 
treated groups as shown in figures 7.9 and 7.10.  Tibia bone showed higher number of 
neutrophils in for both in treated and control group as shown in figure 7.11 which was 
expected to be a normal post surgery inflammatory response in bone, however there was 
not any additional significant change in tibia bone treated with nanoparticles. 
As toxicity is the major issue related to nanoparticles, higher doses of silver or 
silver based nanoparticles shown that they reside in liver [86, 89] and may cause toxicity.   
To confirm the ACB nanoparticles at 1mg/kg b. wt may cause the changes in morphology 
or cause immune response against nanoparticles and could be observed by histological 
studies but the findings did not show any significant changes among groups treated or 
non-treat for liver, spleen or tibia bone. In liver, morphology of hepatocytes was seen as 
normal along with bile ducts and blood vessels and no significant change was observed. 
Similarly for spleen white and red pulp was clearly distinguished without any sign of 
pathogenicity in treated or non-treated groups. Sections of bone were observed for treated 
and non-treated groups and both the groups intercellular bone matrix with osteocytes 
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were observed and no significant difference was seen among the groups. Our findings 
from liver enzymes for treated or non-treated group also suggest there was no significant 
change observed. Moreover, our histological analysis supports the biochemical tests and 
oxidative stress markers which were non-significant comparing to control groups when 
treated with 1 mg/kg b. wt. of ACB nanoparticles.  
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Figure 7.9. Histology of Liver by H&E stain. Upper panel shows Control group treated 
with saline and lower panel Treated group with 1 mg/kg b. wt. of ACB Nanocidals. 
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SPLEEN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7.10. Histology of Spleen by H&E stain. Upper panel shows s,  Control group 
treated with saline and lower panel shows Treated group with 1 mg/kg b. wt. of ACB 
Nanocidals. 
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BONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11. Histology of Tibia bone by H&E stain. Upper panel shows Control group 
with saline and lower panel shows Treated group with 1 mg/kg of b. wt. of ACB 
nanocidals. 
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CHAPTER VIII 
ONGOING STUDIES AND CONCLUSIONS 
Silver-copper nanoparticles which are caped with glycine or embedded in glycine 
were synthesized.  The aim was to produce nanoparticles which are safe for human. The 
newly synthesized nanoparticles need to be characterized for future use in treatment of 
osteomyelitis. It is hypothesized that the efficiency of the newly synthesized 
nanoparticles may be stronger because in this method copper element is protected from 
further oxidation, it has been shown metal copper is more strong antimicrobial than 
copper oxide [55]  
8.1. Synthesis Of Silver-Copper Luminescent Nanoparticles 
2 moles of glycine, 61.6 mmoles of silver nitrate and 26.4 mmoles of copper 
acetate were added to 50 ml conical flask. Dissolved in 10 ml of double distilled 
deionized water and heated till water evaporated.  The solid phase reaction mixture was 
heated at 1700C for 20 minutes by Zheng at al [96]. The reduction of silver-copper was 
monitored by change in color from black to brown with and a silver shine was observed 
to the sides of reaction glass vessel. The dried mixture pellet was re-suspended in 10 ml 
of distilled water and sonicated for two hours using micro-tip probe of 450S-Branson 
Sonicator, 50% power output was kept at maximum limit for micro-tip sonicator 
probe.To remove large aggregates and insoluble nanoparticles, the solution was 
centrifuged at 4000 rpm for 20 minutes, although no aggregates were observed. To 
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remove free glycine, solution was dialysed in water for 24 hours and after every 6 hours, 
replaced with fresh deionized water. The Slide-A-Lyzer Dialysis Cassettes with MWCO 
2K was used for dialysis from thermo scientific  Solution was collected from dialysis 
cassette and stored in 10 ml screw cap glass vial. 
8.1.1. Characterization of Silver Copper polycrystalline nanoparticles 
 
 
 
 
 
 
 
 
 
 
Nanoparticles observed has a core shell and matrix which is formulation of 
glycine by solid phase synthesis, besides central core there are sub cure size grains seen 
in the matrix, suggesting a polycrystalline nature of nanoparticles. SEM imaging was 
performed at 5KV to observe the core shell, sub-core size grains and matrix as shown in 
figure 8.1 and figure 8.2, while as above or below 5KV energy, matrix was not 
differentiated from core shell as shown in figure 8.2-(A,B). At 1.92 KV and 3KV voltage 
nanoparticles appeared as spherical without any details of core or matrix, however it was 
Figure 8.1. TEM and SEM images. TEM Characterization of nanoparticles on left 
and SEM image on right side. 
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found the optimal voltage of 5 KV where matrix was differentiated from core along with 
the sub core size grains in matrix. 
 The data suggests that silver copper nanoparticles are capped with glycine matrix 
and matrix is embedded with 8 to 10 nm size silver-copper nanoparticles, particles in 
matrix were not in agglomerated form but distributed all over the matrix with a minimum 
gap of 10 nm or more, as a result these nanoparticles exhibit as polycrystalline in nature. 
Frequency distribution of size of nanoparticles, core shell and sub core particles in matrix 
are shown in Figure 8.3. 
  Stability of these nanoparticles has proven another add on advantage besides its 
optical properties, they are in same shape and size in aqueous suspension since 6 months. 
Earlier studies has shown the disadvantage of copper nanoparticles or Copper alloy for 
agglomeration because copper is readily oxidized as CuO and keeps growing as Copper 
oxide agglomerate, but our findings did not found any evidence of agglomeration since 6 
months and the reason could be the glycine matrix which prevents nanoparticles from 
oxidation. 
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Figure 8.2. SEM image at different Kv. A and B panels at 1.9 and 3 kv 
respectively, SEM images at 5 kv in panel 2C and 2E. Above 5kv panel 2F. 
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Figure 8.3. Histogram of nanoparticles. These histograms are corresponding to SEM 
images shown in figure 8.2. In this figure Histogram of polycrystalline nanoparticles on 
left, the middle histogram of core size in polycrystalline nanoparticles and on right the 
sub core particles in matrix of poly crystalline nanoparticles. 
 
8.1.2. Spectroscopy techniques  
 We also studied the Absorption, excitation and emission spectra of nanoparticles. 
UV-Vis absorption scan showed maximum Absorption spectrum at 410 nm by using DU-
800 COULTER spectrophotometer as shown in figure 8.4 which was close to silver 
Plasmon resonance of silver but with a wide shoulder which further depicts the optical 
properties of nanoparticles as earlier discussed for silver polycrystalline nanoparticles. 
These nanoparticles may have silver-copper distribution in a ration 80:20 because of 
concentration of moles of Silver and copper ions added during synthesis, Silver-Copper 
hybrid nanoparticles might have dominant silver properties because of higher 
concentration of silver comparing to copper. Fluorometric data analysis showed that there 
was  maximum emission at 460 nm with Excitation at 400 nm, however there was  shift 
in emission spectrum by changing the excitation wavelength from 400 nm to 450 nm at 
interval of 10nm. For each 10 nm increase in excitation there was shift by 10 nm in 
emission, however it was obvious from the data that the intensity of Emission spectrum 
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decreased significantly by changing the Excitation wavelength. Cary eclipse instrument 
was used to study Fluorescence with Ex. Slit (5 nm), Em. Slit (5 nm) and scan rate (300 
nm/min). 
 
 
 
 
 
These luminescent silver-copper nanoparticles needs to evaluated for 
antimicrobial activity and however equally toxicity data must be explored, it is 
hypothesized that these nanoparticles will be the more suitable particles for antimicrobial 
testing with least toxicity associated because they are surface coated with glycine 
molecules. Moreover they can be used for live imaging using IVIS imaging device or 
good source of fluorophore for confocal microscopy.   
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Figure 8.4. Fluorometric and spectrophotometric results. On the left side shown the 
visible spectrum of nanoparticles and on the right side Emission at different excitation 
wavelengths. 
115 
 
8.2. Conclusions  
In this study, results proved the efficiency of nanocidals against s. aureus infe-
ction in in vitro and in vivo with minimum toxicity associated  which was revealed from 
chapters as discussed in this study.  
 Overview of ACL and ACB results: Both ACL and ACB exhibited antimicrobial 
activity, however ACL showed effective antimicrobial activity at 0.5 µg/ml, while as 
ACB nanoparticle showed antimicrobial activity at 1 µg/ml, which was 2 fold difference 
among ACL and ACB, moreover it can be seen that the antimicrobial activity varies with 
incubation time, but the choice of selection was determined by toxicity. The primary aim 
of this study was to find the optimal dose and in this study our optimal dose will be 
minimum concentration which is nontoxic.  From the results it was found that ACL 
nanoparticles showed toxicity at 10 µg/ml which was determined by catalase activity 
however for ACB nanoparticles significant toxicity was shown at 20 µg/ml, except there 
was mild stress observed by protein carbonyl content which was indication oxidation of 
proteins at 15 µg/ml, herby our assumption that ACB nanoparticles may exhibit toxicity 
at this level.  So based on the findings of this study, ACB nanoparticles were chosen to be 
used further for animal model toxicity and in osteomyelitis model.  
  In the animal model of toxicity, the distribution of elements among vital organs 
in just 4 hours and 24 hours post treatment was observed which was the first sign that 
these nanoparticles can go across all tissues in the body, however it is undesirable at 
some point which could not be controlled. The pattern of clearance from organs in 24 
hours post injection was observed but most likely they were abundant in liver. However 
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the permanent retention of nanoparticle in organs cannot be determined in this study, 
which will need analysis of elements for several weeks to months and is one of planned 
future studies.  
 Development of murine model of osteomyelitis with localized infection was 
successfully achieved; primary role of this murine model was to check the efficacy of 
antimicrobial activity which was hypothesized from in vitro studies, the results of 
antimicrobial activity in murine model with induced osteomyelitis was promising. 
Decreasing the concentration of nanoparticles the efficiency of nanoparticles was 
decreased proportionally. Ideally an effective treatment would not have developed 
histopathology or immunogenic response, in this study addition to antimicrobial activity 
biochemical analysis for reduced glutathione to measure the oxidative stress if associated, 
using ACB Nanocidals with 1, 0.5 and 0.1 mg/kg b. wt. were conducted and it was found 
that no significant change was observed. Histological study for bone, liver, and spleen 
tissues were performed and there was no sign of change in morphology of cells nor any 
infiltration of neutrophils alone or blood cells. 
 It is concluded that ACB nanoparticles are a suitable potential for antimicrobial 
therapy for osteomyelitis disease. Further study is required to explore the clearance of 
nanoparticles from organs or tissues with respect to time. 
 In planned future studies silver-copper-glycine polycrystalline nanoparticles will 
also be investigated.  The advantage of these nanoparticles could be less toxic because 
silver and copper is embedded in glycine core which may reduce the toxicity of 
nanoparticles. Another important characteristic of these nanoparticles is they are 
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luminescent they can be tracked in in-vitro studies or can be used in in vivo studies for 
imaging using IVIS imaging device for medical application including osteomyelitis.  
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